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ABSTRACT
Passive antibody treatments are used to target infectious disease, toxins, venoms,
and cancer antigens. Recently, there has been an increased interest in the use of avianderived antibody treatments such as IgY. IgY is the primary serum antibody isotype
present in the avian system, and IgY treatments have already been demonstrated to be
effective against a variety of bacterial and viral infectious agents. There are two forms of
IgY expressed in anseriformes birds, a full length IgY that is functionally similar to
mammalian IgG, and an alternatively spliced IgY, IgY(ΔFc), that is comparable to the
mammalian F(ab’)2 fragment. The difference in structure between IgY and mammalian
IgG, prevents IgY from interacting with mammalian Fc receptors, complement, and other
inflammatory factors. The phylogenetic distance between mammalian and avian species
allows IgY to have a higher avidity for certain mammalian epitopes and a unique
antibody repertoire is developed compared to mammals, further enhancing the
therapeutic potential of IgY.
Our current research is focused on developing goose IgY anti-viral treatments and
ensuring the safety of these treatments in humans. The viral antigens of focus in this
research are dengue virus type 2 (DENV-2) and the Andes virus (ANDV). In an attempt
to generate monoclonal goose IgY antibodies, using modified mammalian hybridoma
techniques, geese were immunized with DENV-2 antigen and blood was collected as a
source of immune B-cells and fused with mammalian myeloma cells. Short lasting,

x

virus- specific IgY producing hyrbidomas were created. To generate ANDV specific
goose IgY antibodies geese were vaccinated with a DNA vaccine PWRG/AND-M,
containing the full-length M genome segment of ANDV, via a needle-free device at two
week intervals up to eight weeks and then at 12 weeks. One year later the same geese
were booster vaccinated with either pWRG/AND(opt) or pWRG/AND(opt2) six times
over a ten week time period. Average neutralizing titers of sera collected from geese six
weeks after the primary vaccination was 10,000. Titers remained at this level for the one
year in between vaccinations and then increased to nearly 100,000 after booster
vaccination. Epitope mapping confirmed the specificity of the goose- derived antibodies
and identified unique highly reactive epitopes. IgY from the initial vaccination
recognized 11 epitopes across the M segment, and an additional 9 epitopes after booster
vaccination. In vivo survival studies in a lethal challenge model of ANDV infection
established the post-exposure treatment potential of the ANDV specific IgY.
To test the safety of the anti-viral IgY treatments for use in humans in vivo and in
vitro safety experiments were completed. In a single injection study, mice were injected
with a single dose of IgY/IgY(ΔFc) or PBS, and in a multiple injection study, rabbits
were injected with multiple doses of IgY/IgY(ΔFc), IgY(ΔFc), human immunoglobulin,
or PBS. Organs were collected after injection, hematoxylin and eosin stained, and scored
by a blinded pathologist for abnormal pathology and/or inflammation. There were no
inflammatory manifestations in the organs from animals in either the single or multiple
injection study receiving IgY/IgY(ΔFc) or IgY(ΔFc). PBMCs and neutrophils were
isolated from fresh human blood and co-cultured with IgY/IgY(ΔFc), mammalian IgG,
and other controls. Culture supernatants were collected at various time points and
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analyzed for the presence of IL-1β, TNF-α, IL-10, neutrophil elastase, and nitric oxide
using kit-based assays. All assays reported less reactivity of goose IgY/IgY(ΔFc) with
human PBMCs and neutrophils compared to mammalian IgG and positive control
mitogens. These results further support the lack of reactivity of avian IgY in the
mammalian system and the benefits of safely using IgY as a treatment in the mammalian
system.
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CHAPTER I
INTRODUCTION
Avian Immune System
Though the main objective of the avian immune system remains the same as that
of the mammalian immune system, to prevent any foreign antigen from causing an
infection, and to keep internal antigens in check, the two systems are structured and
function differently. Most research completed to understand, the avian immune systems
has utilized the chicken as a model system; consequently the most is known about the
immune system of the galliformes (land fowl) order of birds. Despite being closely
related to other orders of birds, such as the anseriformes (waterfowl, e.g., geese and
ducks), not everything discovered in chickens can be directly applied to the immune
systems of all birds. The primary lymphoid organs of the avian immune system are the
thymus, bone marrow, and the bursa of Fabricus (BF). The secondary lymphoid organs
include the spleen, harderian gland, germinal centers, and other diffuse lymphoid tissues
[1]. One major difference between the avian and mammalian immune system is the
presence or absence of lymph nodes. Chickens are reported to not have lymph nodes,
while researchers have identified what are believed to be lymph nodes in ducks [2].
Lymph nodes are the primary site of antigen presentation in the mammalian immune
system and are crucial for the development of a proper immune response. It is unknown
for sure where this crucial interaction between antigen and immune cell takes place in
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chickens. It is speculated to occur locally at the site of infection, probably in one of the
many lymphoid aggregates of the mucosal tissue [3].
The thymus is the primary location for the development of T-lymphocytes (Tcells), including initial development and maturation. There is also a small percentage of
B-lymphocytes (B-cells) in the thymus that is dependent on the age of the bird [1]. The
BF is an organ unique to the avian immune system and is the sole site of B-cell
differentiation and synthesis [4]. Glick and Chang have shown that removal of the BF
results in the elimination of the antibody response in the majority of bursectomized
chickens [5]. Bursectomized birds, unlike thymectomized birds, lack immunoglonulins,
splenic germinal centers, plasma cells, and an antibody response, but were capable of a
graft-versus host response, and produced normal numbers of circulating small Tlymphocytes [6]. The bone marrow is the source of precursor stem cells for both B and Tcells that then migrate to the BF and thymus respectively for further differentiation. In
the avian system the spleen is the primary site for plasma cell proliferation and memory
B-cell maintenance [7,8]. The spleen is not only an important organ for lymphocyte
development, but is also the location for granulocyte production, antibody production,
and is important for antigen processing [1]. Some important lymphoid organs within
these mucosal lymphoid tissues are the Peyer’s patches and harderian gland. The Peyer’s
patches are a location of lymphoid cell accumulations in the gastrointestinal tract and
appear to be a major site for IgA responses to pathogenic organisms and undigested
antigens [9]. The harderian gland is part of the head associated lymphoid tissue located
behind the eyeball within the orbit. Plasma cells make up a large percentage of the cells
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in this gland, serving as the major antibody secreting gland of the lacrimal apparatus and
are important in development of vaccine immunity [1,10].
The avian immune response can be divided into two major parts, the innate and
adaptive immune response. The innate immune response is activated during the acute
phase of infection and involves both a non-specific barrier protection and a portion of the
response that is specific, not to individual pathogens, but to classes of pathogens. Some
examples of non-specific physical barriers that are part of the avian immune system
include the skin, mucus membranes, and gastric juices. The more specific portion of the
innate response depends on the cellular components of the innate immune system
including natural killer cells, monocytes/macrophages, and heterophils. The innate
cellular components of the avian immune system are simplified compared to the
mammalian system, lacking eosinophils, basophils and neutrophils [3]. Avian
heterophils are functionally similar to mammalian neutrophils being the predominant cell
responding to innate inflammatory reactions in chickens [11]. Heterophils are highly
phagocytic; most of the antimicrobial activities are carried out through phagocytosis and
the release of granules within the cell [11]. Some of the innate avian immune cells also
have receptors present on their surfaces and endosomes called pattern recognition
receptors (PRRs), which can recognize different types of antigens referred to as pathogen
associated molecular patterns (PAMPs). One well studied group of PRRs are the Tolllike receptors (TLRs). Research suggests that mammals and chickens have different TLR
repertoires, but the basic function is the same [12-14]. The interaction between PRRs and
PAMPs can influence the production and release of cytokines, chemokines, and other
inflammatory mediators by immune cells that influences all subsequent steps of the
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immune response. Cytokines and chemokines are a broad group of secreted intracellular
messengers that serve to coordinate both the innate and adaptive immune responses as
well as immune cell development and homeostasis. These intracellular messengers can
be secreted by many different cell types and can exert their regulatory effects on immune
system cells, hematopoietic stem cells, and non-immune tissues to aid in immune host
defense and homeostasis. Some of the major groups of cytokines include interferons
(IFNs), interleukins (ILs), and colony stimulating factors (CSF). Compared to the
mammalian system, fewer cytokines and chemokines have been identified in the avian
system [15,16]. The human genome has 129 cytokine and chemokine sequences, while
the chicken has only 77 [17].
If the innate immune response is unable to clear the antigen, activation of the
adaptive immune response is required. Activation of the adaptive immune response will
also result in the formation of immunological memory, leaving the bird with a potential
advantage in the future. The innate response is able to influence the adaptive immune
response through cytokines, chemokines, and other inflammatory mediators. A key
bridging point between the two responses is the presentation of antigen in the context of a
major histocompatibility complex (MHC) on the surface of antigen presenting cells
(APCs) such as dendritic cells (DCs) and macrophages (MOs). There are other cells that
act as phagocytes within the avian system: thrombocytes (functional homologs of
mammalian platelets, which are absent from birds) [18,19], and heterophils. Depending
on the type of antigen, either the cell-mediated or humoral immune response is
preferentially developed against the antigen. T- and B-cells are the primary effector cells
of the adaptive immune response and are responsible for the cell-mediated and humoral
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immunity. The preferential development of either the cell-mediated or humoral
responses are driven in part by two subsets of CD4+ helper T-cells: Th1 and Th2.
Expansion of one the T-cell subsets over the others are dependent on the cytokines in the
milieu during the immune response. The Th1/Th2 CD4+ T-cell subset paradigm has been
demonstrated in chickens [20]. What remains unclear however is whether other T-cell
subsets (e.g. Treg, Th17 and Th9), exist within the avian immune system. It is thought in
the avian immune system typically an endogenous antigen is recognized by the CD8+ Tcell subset, in the context of MHC I, leading to activation of the cell-mediated immune
response. CD8+ T-cells become cytotoxic, capable of antigen-specific killing of infected
cells. An exogenous antigen activates CD4+ T-cell subset, when presented on the surface
of an APC in the context of MHC II. CD4+ T-cell subsets are termed T helper cells, they
are responsible for helping with antigen-specific activation of B-cells, aiding in the
humoral immune response along with providing help to macrophages, NK cells, and
CD8+ T cells [3]. The end result of the immune response is clearance of the pathogen and
development of memory.
The effector cells of the humoral immune response are antibody producing Bcells with antibodies carrying out the major functions of the humoral response. Within
the avian immune system there are three classes of immunoglobulins (IgM, IgA, and
IgY), all of which have been identified immunochemically [21] and genetically as
homologs to mammalian IgM, IgA, and IgG [22-24]. Avian IgM is structurally and
functionally homologous to mammalian IgM; it is present in the serum as a high
molecular weight pentamer and is the first antibody produced during a primary antibody
response. IgA is also similar to its mammalian homolog and is able to be found in the
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serum of birds, bile, and tears. IgY is generated typically during a secondary antibody
response and behaves in part like mammalian IgG and mammalian IgE. In anserifomes
birds there is an additional structurally different isoform of IgY that is termed IgY(ΔFc).
During egg formation, IgY in the serum is selectively transferred to the yolk via a
receptor on the surface of the yolk membrane specific for IgY translocation, transferring
immunity from the hen to the developing embryo [25-28]. The amount of IgY
transferred is directly proportional the IgY serum concentration [27]. Both avian IgA and
IgM can be found in the egg white [29]. So far there have not been any identified avian
homologs of mammalian IgD or IgE [23].
As mentioned previously the organs in the avian immune system that are
responsible for antibody production differ from those utilized in the mammalian system.
The primary lymphoid organ responsible for the differentiation of stem cells into B-cells,
as well as diversification, is the BF [4]. The spleen is where plasma cells and memory Bcells can be found. There are various mechanisms used by the immune system to
generate the necessary antibody diversity, the primary mechanisms used do differ
between the mammalian and avian systems. In the avian system the primary antibody
repertoire is generated primarily by a process of somatic gene conversion and by somatic
point mutations. Committed precursor B-cells enter the BF with fully rearranged
immunoglobulin genes and rely on upstream pseudogenes to create diversity for both
light and heavy chains [30-32]. Antibody gene rearrangement in birds takes place in the
developing embryo during a 10 day window prior to hatching. The antibody light (L)
chains are mostly of one type (λ) [33], meaning the genomic L chain locus is made up of
one constant region (CL or Cλ). The rest of the L chain locus is made up of a single
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unique junctional region (JL), which undergoes rearrangement to the adjacent function
variable region gene (VL) [33]. The same VL and JL segments are used in all B-cells
during VJL rearrangement, limiting the diversity that can be gained within the L chain
from the process of gene rearrangement. A similar organization has been characterized
for the heavy (H) chain locus. There is one V region (VH), a single J segment (JH), used
in all B-cells, and approximately 15 function diversity (DH) segments [24,34]. The H
chain immunoglobulin gene loci also contain constant region genes μ, ν, and which allow
for the production of IgM, IgY and IgA respectively. Because there are multiple DH
segments there is a minimal amount of junctional diversity generated from VDJH
rearrangement. There is potential for rearrangements with fused D-D elements, due to
the sequence homology between the DH segment sequences [23]. Unlike in the bone
marrow of the mammalian system there is no specific order in which the rearrangements
need to take place; rearrangement of one chain is not dependent on the other. In fact
VDJH and VJL rearrangements have been detected at the same time in the developing
embryo [35].
After successful gene rearrangement primary antibody diversity is generated
through the use of pseudogenes and somatic gene conversion. Both the immunoglobulin
L and H chain gene loci have pseudogenes upstream from the VL and VH regions.
Upstream from VL is a group of appxomimately 25 psdeudogenes (ΨVL), and upstream
from VH there are approximately 80 pseudogenes (ΨVH) [36]. These gene segments are
defined as pseudogenes because they typically lack the promoter sequences required for
transcription, have a truncated 5’ or 3’ coding region, or lack the necessary
recombination signal sequence (RSS) [33]. The process of somatic gene conversion
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starts approximately 15-17 days after the immature B-cells migrate to the BF [37].
Diversity is ultimately generated when sequences derived from the upstream pseudogenes
replace homologous sequences within the V region of rearranged VJL or VDJH genes and
undergo gene conversion [38]. After gene conversion is complete, the B-cells have
reached the end of their time in the BF and migrate into the periphery. B-cells usually
start to migrate from the BF in the last few days before the bird hatches. At first the
percentage of cells migrating from the BF is low. After hatching about five percent of
bursal B-cell migrate each day into the periphery through the blood and then into the
spleen, thymus and caecal tonsils, where they will eventually produce antibodies and be
active in the humoral immune response [36,39]. The remaining percentages of bursal Bcells end up dying in the bursa during various steps in development due to autoreactivity,
or nonproductive H and L chain rearrangements. However, B-cells deaths are rarely due
to the process of gene conversion, that process is ~98% successful [40,41]. It has been
observed that by the time baby chickens reach the age of four weeks a sufficient number
of B-cells have migrated out of the BF. At that point the B-cell immune system is
considered mature in the periphery, resulting in involution of the BF [42]. Once the Bcells are in the periphery, the spleen is responsible for maintenance and proliferation of
plasma cells and memory B-cells.

Function and Structure of IgY Antibodies
Structural and functional research shows avian IgY is similar to mammalian IgG.
Avian IgY is the functional equivalent of mammalian IgG within the avian immune
system, acting as the major system antibody responsible for defense against infectious
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diseases. Unlike IgG, full length IgY is also able to sensitize tissues to anaphylactic
reactions [43]. Structurally avian IgY is similar to mammalian IgE based on size and
number of exons. IgY is classified as a low-molecular weight (LWM) immunoglobulin,
thus it is made up of two H chains and L chains with a molecular mass of ~180kDa [44].
Each of IgY’s L chains consists of one variable and one constant domain with a
molecular weight of ~18kDa. The H chains of IgY have one variable domain and four
constant domains denoted Cν1-Cν4, with a molecular weight of ~65kDa [44]. As was
mentioned previously, IgY is structurally similar to mammalian IgE. Both of these
antibody’s H chains have four constant domains and are lacking a hinge region. It is also
the H chains that structurally differentiates mammalian IgG from IgY. The H chains of
mammalian IgG have only three constant domains (Cγ1-Cγ3) with molecular weights of
~59kDa each, causing the molecular weight of IgG to be only ~159kDa, less than that of
IgY. Sequence comparison between IgG and IgY has shown that the Cγ2 and Cγ3
domains of IgG are closely related to the Cν3 and Cν4 domains of IgY, while the
equivalent Cν2 domain is absent in the IgG H chain [45,46]. The Cν2 domain that is
present in IgY is thought to have been replaced by the hinge region in IgG [23]. This is
supported by the observation that the hinge region of IgY is much less developed
compared to IgG, and the flexibility of IgY is also decreased compared to IgG [45]. The
lack of a developed hinge region in IgY may account for some of the differences in
function between the two types of antibody.
There is an additional isoform of IgY that can be found in anseriformes birds,
which lacks two C-terminal constant domains (Cν3-Cν4) of the H chain. This isoform of
IgY is referred to as alternatively spliced IgY or IgY(ΔFc) and has a molecular weight of
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~120kDa. IgY(ΔFc) and full length IgY may coexist in an individual organism as they
do in anseriformes birds, or one form may be produced exclusively. For example,
chickens only produce full length IgY. Both full length IgY and IgY(ΔFc) are products
of a single gene generated by alternate pathways of mRNA processing [47,48]. Despite
being from the same genetic source IgY and IgY(ΔFc) do have some functional
distinctions. During an immune response the IgY(ΔFc) isoform is found later in the
immune response than full length IgY [49]. In the avian immune system, full length IgY
is able to fix complement and sensitize tissues to anaphylaxis, but both of these immune
functions are not carried out by IgY(ΔFc) [49]. These functional differences between the
isoforms are most likely due to the alternatively spliced isoform lacking the two terminal
Fc domains. This limits IgY(ΔFc) to functions that do not require secondary effector
functions such as virus neutralization. It is even possible that IgY(ΔFc) was tolerated
evolutionarily because of its inability to sensitize the host birds to IgE-like reactions
leading to less host damage.

Physiochemical Properties of IgY and IgY(ΔFc) Antibodies
Other properties of IgY that differ from mammalian IgG include β-sheet content,
hydrophobicity and isoelectric point. The β-sheet content of IgY, especially in the
constant domain, is lower than that of IgG [50]. Decreased β-sheet content has the
potential to cause a more disordered conformation in IgY leading to a less stable antibody
than IgG. IgY is also more hydrophobic than IgG. This is due in part to the fact that the
Fc fragment of IgY is larger than that of IgG, and the fact that the Fc portion of the
antibody is the most hydrophobic part of the antibody molecule. Experiments completed

10

comparing the kinetics of either IgG or chicken IgY interacting with latex particles under
varying conditions further support the increased hydrophobicity of IgY versus
mammalian IgG [51]. The isoelectric point of IgY is in the range of 5.7 to 7.6, lower
than that of IgG [52].
The use of IgY as a potential passive therapeutic is dependent on the ability of the
antibody to remain stable and active when exposed to a variety of environmental
conditions including heat, pH, and proteolytic enzymes. When compared to rabbit IgG,
IgY is much less stable during acid denaturation. IgY has been found to be stable in a
range between pH 4 to pH 11, but above or below this range IgY activity decreases
[53,54]. IgY activity is decreased at a pH of 3.5 and completely lost at pH 3, while rabbit
IgG activity is not lost until pH 2 [50,55]. The stability at harmful pH’s can be improved
by adding different carbohydrates of sugars to act as stabilizers [56,57]. Temperature is
also a threat to the activity of IgY. Researchers have reported that as temperature
increases, IgY activity decreases. Heating IgY to a temperature of 60-65ºC will result in
a minimal loss of activity, but the major decrease in activity is reported at temperatures of
70ºC or higher, when heated for more than 15 minutes [50,53,55]. The addition of sugars
can help IgY to maintain activity at higher termpatures in the range of 75-80ºC [57].
IgY is also susceptible to proteolytic cleavage by enzymes such as pepsin, trypsin,
and chymotrypsin. In general, IgY has been found to be more resistant to the activity of
trypsin and chymotrypsin than that of pepsin. Almost all IgY activity is lost after
digestion with pepsin while, on the other hand IgY remains active even after eight hours
of incubation with trypsin or chymotrypsin [53]. The sensitivity of IgY to pepsin seems
to be dependent on the pH and enzyme to substrate ratio [53]. Different variations of pH
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and enzyme to substrate ratio will yield different effects on IgY activity. Overall, IgY is
more susceptible to all three of these proteolytic enzymes that IgG. These differences in
susceptibility could be related to the structural differences between the two antibodies,
including the lower β-sheet content of IgY along with the lack of a hinge region [50].
Both of these structural characteristics have an impact on the overall properties and
stability of the IgY molecule.

Advantages of Passive IgY Antibody Immunotherapy
Avian IgY antibody treatments have many advantages over traditionally used
passive antibody treatments, some of which stem from the phylogenetic distance between
the mammalian and avian species. The phylogenetic distance leads to an increased
immune response in birds when compared to mammalian antibodies. The IgY produced
has a higher avidity for mammalian antigens, and recognizes different epitopes compared
to mammalian antibodies, creating a unique antibody repertoire [58,59]. Even when
mammals and birds are identically immunized often times different antibody specificities
will develop in birds than mammals. Di Lonardo et al. showed through epitope mapping
that when rabbits and chickens were immunized with the same antigen, in this case
human papilloma virus type 16E7 oncoprotein (HPV16E7), the resulting antibodies
recognized different peptides[58]. Eight HPV16E7 peptides were used for the epitope
mapping; the chicken antibodies reacted to all eight peptides, while the rabbit antibodies
only reacted with two peptides [58]. In another example, eggs from immunized chickens
were used as a source of IgY antibodies against the insulin receptor of rats, as a means to
gain more information about the function and structure of the insulin receptor. Previous
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results utilizing rabbit antibodies against the α-subunit of rat insulin receptors did not
entirely mimic the insulin resistance response seen in patients that naturally produce
antibodies against insulin receptors. In order to better mimic the natural human
syndrome, chicken IgY antibodies against insulin receptors were generated. The
properties of the IgY antibodies were similar to those of the antibodies found in the
human disease and caused the inhibition of insulin binding, stimulated glucose oxidation,
and autophosphorylation of the insulin receptor [59]. Rabbit antibodies of the same
specificity failed to mimic all of the same effects as the IgY antibodies, mainly insulin
binding was not prevented [59]. These are just two examples that clearly demonstrate the
avian IgY antibodies ability to recognize different epitopes than mammalian antibodies,
regardless of the origin of the antigen. For some mammalian antigens IgY antibodies
have increased binding specificity and sensitivity compared to mammalian antibodies.
IgY can be used to make antibodies against conserved antigens within the mammalian
system, in some situations there may be no other option if the antigen is too highly
conserved [60]. Using IgY antibodies from the eggs of immunized birds offers
researchers access to a different antibody repertoire than what can be achieved with the
mammalian techniques currently used.
A key advantage to the use of avian IgY antibodies is being able to utilize the egg
as the source of the antibodies. Eggs can be easily harvested from laying birds,
eliminating the need for bleeding animals representing a non-invasive and more humane
method of obtaining antibodies that meets current regulations regarding animal use in
research. Not only is it less invasive, but an equivalent or greater amount of antibodies
can be isolated from the egg yolks of a chicken, duck, or goose egg compared to what can
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be isolated from the serum of rabbits or other animal sources of antibody. The amount of
IgY purified from a chicken egg can vary depending on age and breed of the hen, along
with the antigen used for injection, from 60-150mg per egg [61,62]. Based on the laying
habits of chickens the average monthly antibody production is in the range of 1000 to
2800 mg [37]. Goose eggs are larger than chicken eggs increasing the amount of IgY
that can regularly be purified from a single goose egg to 500mg. In comparison, to
isolate 200mg of mammalian IgG from rabbit serum it would take approximately 40mL
of blood which is total amount of IgG available for the month [37]. Because IgY levels
in eggs can be influenced by bird age, studies have been completed comparing laying
patterns to IgY content of eggs from laying hens over an extended period of time. When
laying hens were monitored for a two year period, there was a decline in the laying
capacity of the hens in the second year. However, there was also an increase in the total
IgY per egg, balancing out the decrease in egg numbers [62]. Antigen specific IgY titers
remained stable during the two year time period and the IgY was functional [62]. These
findings are supported by the observations of Trot et al. that older hens have higher IgY
titers compared to younger hens. When taking into consideration both egg mass and
laying frequency, young hens in the study had a 1.3 fold increase in total egg mass
compared to older hens, but this difference was offset by a 1.5 fold increase in IgY titers
in older chickens [61]. Not only can eggs easily be collected from their avian sources,
IgY can also easily be isolated from the egg yolk. Throughout literature various methods
have been described to isolated IgY from the egg yolk, but all utilize one or more the
following basic lab procedures: precipitation, chromatography, and/or ultracentrifugation.
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Some labs are extracting IgY from eggs on an industrial scale, supporting the potential
large-scale production of IgY therapeutics [63,64].
Most biological effector functions of immunoglobulins are activated by the Fcregion. As described above, the Fc region is where the major structural differences
between IgG and IgY are located; which leads to a difference in Fc dependent functions
between the mammalian IgG and avian IgY molecules. This difference can be used to
prevent interferences in immunological assays as well as adverse reactions within the
body caused by rheumatoid factor (RF), complement activation, human anti-murine
antibodies (HAMA), or binding to human and bacterial Fc receptors. There are
antibodies within the body that react with the Fc portion of mammalian IgG antibodies,
one example is RF. Most of the time RF is an autoantibody associated with rheumatoid
arthritis (RA), but it can be found in the patients with other diseases and in the blood of
healthy individuals [65]. HAMAs form often when antibodies are used for treatment or
imaging. More specifically, the murine antibody is seen as a foreign protein by the
human body, which triggers an immune response resulting in the formation of HAMAs.
In some cases HAMAs have also been found in the serum of patients who have not been
treated with antibodies [66]. The HAMA response can persist in the blood for several
months, and can be easily reactivated if memory B-cells are formed. This response can
interfere with assays used in diagnosis and/or surveillance of disease and cause
potentially painful symptoms for the patients. Attempts have been made to prevent the
HAMA response by making humanized antibodies through replacement of the Fc portion
of murine antibodies with the constant region of human antibodies. Some of these
engineered antibodies are only 10% murine or even “fully human.” These engineered
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antibodies have protein epitopes that can be seen as immunogenic by the human immune
system and ultimately cause an antibody response by the body. This response is referred
to as an anti-drug antibody response (ADA). The HAMA/ADA responses within the
body can result in a variety of symptoms from more mild allergic reactions, generalized
pain, hponatremia, fever, rigors, chills, rash, paresthesia, weakness, chronic refractory
postural hypotension [67,68], to hypersensitivity reactions that range from serum sickness
with urticarial and bronchosapsms [68-72], to anaphylactic shock [73-75].
HAMA/ADAs can be classified as either binding antibodies (Bab) or neutralizing
antibodies (Nabs) depending on if they alter the pharmacokinetics of the antibody
treatment and/or lead to symptomatic reactions in the body [76-79]. Babs bind to sites on
the antibody that do not directly interfere with the ability of the antibody to interact with
the intended target of the antibody. They can affect the pharmacokinetics, specifically
the clearance of the antibody treatment from the body before it can function properly [7981]. Nabs bind to sites on the antibody that are important for ligand-receptor interaction
thereby inhibiting antibody function; this can cause diminished efficacy and lead to
failure of the treatment [82-84]. Nabs are primarily of the IgG isotype and more
commonly cause life-threatening conditions that Babs [73]. Using IgY antibodies as an
alternative to current IgG antibody treatments on the market comes with a decreased risk
of adverse reactions because IgY antibody does not interact with human RF or cause
HAMA/ADA responses [84-86]. IgY can also be used to replace mammalian IgG in
immunoassays to avoid interference from RF or HAMA/ADAs produced during
treatment with mammalian IgG [86,87]. Reduced interference in immunoassays will also
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decrease the number of false positive results and unnecessary medical procedures done
because of inaccurate test results.
The complement pathway is another example of an Fc- dependent function that
IgY antibodies are unable to activate because of the distinctive structure of their constant
region. Within the avian immune system IgY antibodies binding to antigens are able to
bind to activate the complement system. The same is not true when avian IgY antibodies
are placed in human immune conditions. Avian IgY antibodies do not activate the human
complement system [88]. In the mammalian system, under normal conditions antibodies
react to antigen to form an antibody-antigen complex. The Fc portion of the antibody can
then activate the complement system and lead to recruitment of inflammatory cells,
opsonization of pathogens, and killing of pathogens. When the complement pathway is
inappropriately activated it can lead to unnecessary inflammatory reactions. The
anaphylatoxins C4a and C5a products of the complement pathway are often responsible
for initiating parts of these inflammatory responses. The anaphylatoxins are able to
stimulate mast cells to trigger IgE-independent histamine release as well as TNF-α
release [89]. This can mimic allergic shock depending on the number of mast cells
involved [90,91].
A serum sickness-like illness can also develop depending on the number of
complement immune complexes formed during the course of treatment. Serum sickness
can also result from complement-binding immune complexes, which can lead to
activation of leukocytes and then to widespread tissue damage. Though the disease is
usually self- limiting, after a second dose of antigen the illness will follow the same
kinetics as a secondary immune response. C5a also acts directly on neutrophils and
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monocytes to increase their adherence to vessel walls, their migration towards sites of
antigen depositions, and their ability to ingest particles [89] further contributing to the
progression of serum sickness.
Complement activation is dependent on the carbohydrate determinants in the Fc
region of antibodies; the composition of antibody subclasses IgG1 and IgG3 make them
most effective at complement activation [92,93]. IgY is unable to initiate the
complement cascade in mammals due the difference in the Fc portion of the antibodies.
IgY is thought to be lacking the necessary carbohydrate determinants to activate the
complement pathway. This prevents both complement-mediated and antibody dependent
cell-mediated lysis from taking place in the presence of IgY [37]. IgY therapeutics have
the potential to avoid many of the adverse reactions, including unnecessary inflammatory
reactions, in patients caused by mammalian IgG activation of the complement pathway.
The activation of the complement pathway by IgG can also interfere in immunological
assays, causing problems with background and test result errors. The lack of complement
pathway activation by IgY also makes it a useful reagent in immunological assays,
especially those that utlize serum, decreasing the background and reporting errors
[88,94].
There is evidence that IgY, depending on the source, does not interact with
bacterial proteins that are immunoglobulin Fc-binding. The most well-known of these
proteins are Staphylococcal protein A and Streptococcal protein G. These proteins are
able to bind to the Fc portion of IgG from many mammalian species [95,96]. The
interaction between the bacterial proteins and IgG is utilized in purification assays and
immunoassays. Problems can arise from this interaction depending on the assay and
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specimen leading to false positives. Results of initial research using chicken antibodies
reported that IgY does not react with Staphylococcal protein A Streptococcal G [95-98].
There have been conflicting results regarding whether or not IgY from anseriformes birds
interacst with bacterial Staphylococcal protein A and Streptococal protein G. Research
by Kronvall et al., using various methods, report that IgY from anseriformes birds does
not interact with Staphylococcal protein A or Streptococcal protein G [97]. In some
studies duck IgY has been reported to bind strongly to Staphylococcal protein A, but
poorly to Streptococcal protein G in Sepharose affinity columns [2]. A more recent study
completed by Justi-Valliant et al. compared the reactivity of immunoglobulins from
various avian and mammalian species with Staphylococcal protein A and Streptococcal
protein G, and other bacterial proteins. In this study, using a direct ELISA, duck IgY was
found to react with Staphylococcal protein A while chicken IgY was unreactive. Overall,
direct use of ELISA demonstrated that duck IgY reactivity was less than that of many
mammalian species [99]. When tested via sandwich ELISA, duck serum did not react
with Streptococcal protein G, and chicken IgY was also unreactive. By contrast all
mammalian species were reactive with Sreptococcal protein G.
The interaction of avian IgY antibodies with bacterial Staphylococcal protein A
and Streptococcal G is most likely not Fc mediated, as it is in mammals, because of the
difference in the Fc portion of the antibodies between avian IgY antibodies and
mammalian IgG antibodies. This is especially true for IgY(ΔFc) produced by
anseriformes birds, which is lacking both CH3 and CH4 domains. It is more likely that
IgY interacts with the bacterial proteins through the CH1 and CH2 domains of the
immunoglobulin, although some involvement of the other domains cannot be ruled out.
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Differences in reactivity between chicken IgY, duck IgY, and potentially other
anseriformes birds could be due to differences in the histidine (His) content of H chains
of the two avian species. Research with human IgG suggests that His residues in the Fc
region are important in binding to protein A [2]. Duck IgY H chains have eight unique
His residues compared to chicken IgY: four in CH1, one in CH2, two in CH3, and one in
CH4. Most likely to be involved in binding to Staphylococcal protein A are those in CH1
and CH2 [2]. Using avian IgY antibodies in assays is advantageous because of the lack of
interaction between avian IgY antibodies and bacterial proteins that are Fc binding. This
lack of interaction can lead to a reduction in the interference problems in assays seen with
mammalian IgG.

Passive Immunization
Passive immunization makes use of the ability of artificial passive immunity to
treat or prevent a foreign attack- often infectious agents. In this type of immunity,
antigen- specific antibodies or serum from another source, typically an immune human or
animal, is given to another individual for protection. The protection conferred is
immediate and will last as long as the transferred antibodies remain in the recipient’s
body. Passive antibody therapeutics have been around since the late 19th-20th centuries
with pioneering research done by Robert Koch, Emil von Behring, and Paul Ehrlich. This
research started with the observation that blood from rats who were resistant to anthrax
was able to kill the anthrax bacterium in later experiments [100]. These researchers
worked to develop products termed antitoxins, antibodies, and magic bullets, all the
predecessors of today’s monoclonal antibody therapeutics [100,101]. Advancement in
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technology led to the design of intravenous immune globulin (IVIG). In this process,
antibodies from patient’s serum were isolated and then used to treat immune and
infectious diseases [102-104].
A major discovery was made in 1975, with Kohler and Milstein’s development of
a method for the isolation of monoclonal antibodies from hybridoma cells. Kohler
identified how to obtain antibodies from mortal B-cells in culture, while his colleague
Milstein found a way to transform myeloma cell lines and promote cell fusion. Joining
together they generated a method for fusion of immortal myeloma cells and antibody
producing B-cells that secrete a single monoclonal antibody recognizing a specific
antigen [105-107]. The first therapeutic monoclonal antibody approved by the Federal
Drug Administration for human use in 1986, was murononab, a murine derived antibody
used for acute organ rejection [107]. Since then the field has accelerated quickly with 25
therapeutic antibodies currently in clinical use and many more in development.
Most therapeutic antibodies used today are of murine origin, most likely due to
the early development of mouse hybridoma technology. But the use of murine antibodies
has its limitations. The efficacy of murine- derived antibody therapeutics is challenged
by their potential for high immunogenicity in humans. The HAMA response after murine
monoclonal antibody treatment in severe cases can result in anaphylaxis. Not only does
the HAMA response adversely affect the patients, but the antibody can also be
inactivated and eliminated from the body before it can function properly. Murine
antibodies can generate a less than ideal protection in humans, reacting with epitopes that
are not protective [101]. There has been an increasing interest in the use of avian
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antibodies as passive immune therapeutics. Many of the weaknesses of current
therapeutics can be resolved by using avian IgY antibodies.

Passive IgY AntibodyTreatments
Current research using polyclonal avian IgY antibodies as a potential passive
antibody treatment is ongoing in both the veterinary and human fields. The goal of a
majority of these treatments is to establish protective immunity in the host by delivering
pathogen- specific avian IgY antibodies to the host. Polyclonal antibodies have been
made against a variety of infectious disease agents including bacteria, viruses, fungi,
toxins, and venoms. Their effectiveness has also been tested in a number of disease
models and human trials. A few representative examples are reviewed below.
Pseudomonas aeruginosa
The most successful clinical application of avian IgY antibodies has been the
prevention of Pseudomonas aeruginosa (P. aeruginosa) colonization in cystic fibrosis
(CF) patients. CF is a hereditary, life threatening disorder with repeated respiratory
infections and malnutrition as main clinical manifestations [108]. Chronic lung
infections with P. aeruginosa are a major cause of morbidity and mortality in CF
patients, and are accompanied by a more rapid deterioration in lung function. Usually
these P. aeruginosa infections are treated with antibiotics, which can help to reduce, and
sometimes clear the infection. However, the infection often continues to reappear until
the patient is chronically infected and the P. aeruginosa becomes impossible to eradicate
[109-115]. Chronically infected patients need to be continually treated with antibiotics;
this continual treatment can lead to secondary infections, bacterial resistance, allergic and
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toxicity reactions, and negative effects on commensal flora [116-119]. Anti- P.
aeruginosa IgY has been and is continuing to be researched as a complement and standalone treatment for P. aeruginosa in CF patients. It is impossible to eradicate P.
aeruginosa once a person becomes chronically infected. As a short term treatment antiP. aeruginosa IgY could be used to prolong the amount of time between infections. As a
long-term treatment avian IgY antibodies could be used to decrease the number of P.
aeruginosa infections and prolong the onset of chronic P. aeruginosa infection.
In vitro studies have already established the potential of the anti- P. aeruginosa
IgY antibodies to prevent P. aeruginosa infections by blocking the ability of the bacteria
to adhere to the epithelium in the oropharynx and thereby prevent the bacteria from
entering the lower airways [66,120]. For in vivo research Kolberg et al. developed P.
aeruginosa specific avian IgY antibody by immunizing white leghorn hens with
formaldehyde-fixed P. aeruginosa [120]. Eggs were collected from immunized hens and
IgY was isolated from the egg yolks. The anti- P. aeruginosa IgY was then prepared in
such a way that CF patients could use it as a mouth rinse. Experimental group CF
patients were instructed to gargle with the IgY mouth rinse for two minutes and then
swallow it every evening after their final meal and brushing teeth. The goals of this in
vivo study were two-fold. First, to see if daily use of anti- P. aeruginosa IgY could
prolong the length of time between the first and second P. aeruginosa colonization in
patients that are not yet chronically infections. The second goal of this research was
centered on long-term treatment and if continuous use of the anti- P. aeruginosa IgY
mouth rinse could decrease the intermittent colonization rate and prevent chronic
infection, ultimately decreasing the need for antibiotics. Based on results from sputum
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samples collected from CF patients throughout the study, the amount of time between the
start of treatment and the next P. aeruginosa positive culture was longer in patients
treated with anti- P. aeruginosa IgY than the control treatment. Though the trend was
obvious, the difference was not significant. In long-term study, the 10 CF patients in the
experimental group participated for an average of 57 months and the 21 control group CF
patients participated for an average of 36 months. There was a total of only 14 positive
cultures in the anti- P. aeruginosa IgY treatment group out of a total 315 (4.4%) cultured
that were positive for P. aeruginosa. In comparison, the control group patients had 105
positive cultures out of the 315 collected during the study (18.7%) [120]. Also, none of
the 13 patients in the experimental group became chronically colonized with P.
aeruginosa, while 5 of the patients in the control group did become chronically colonized
[120].
A similar experimental design was followed in in vivo studies completed by
Nilsson et al. in 2008 to determine the efficacy and adverse reactions of long-term
treatment with anti- P. aeruginosa IgY [108]. Results were similar, chronic colonization
occurred in only 2 of the 17 CF patients treated with anti-P. aeruginosa IgY, but in 7 of
the 23 CF control treatment CF patients [108]. The median time to reinfection after
treatment in the control treatment group was 19 months and in the anti- P. aeruginosa
IgY treated group it was 25 months [108]. These results support the use of anti- P.
aeruginosa IgY as a means to decrease the number of P. aeruginosa infections over a
given length of time and to prevent chronic P. aeruginosa infections.
Additional studies were completed to gain more insight into the mechanism that
leads to the decrease in colonization reported after treatment with anti-P. aeruginosa IgY.
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It was determined that the anti - P. aeruginosa specific IgY binds to flagellin present on
the surface of the bacteria, which may prevent P. aeruginosa in CF patients by hindering
host infections due to reduced adherence. The avian IgY antibodies may be able to
directly affect adherence or indirectly reduce the bacteria’s motility [121].
Streptococcus mutans
The mircobiota within the oral cavity is important in host defense, acting as a
barrier by creating unfavorable conditions for exogenous organisms that might be
pathogenic to the host. Under the right conditions, some of the bacteria present in the
mouth can cause infections, including dental caries, which are most often caused by
Streptococcus mutans (S. mutans). Dental caries result from interactions between the
host, diet, and the microflora on tooth surface [122]. Virulence factors of S. mutans
include adherence to the enamel surfaces of the tooth, production of acidic metabolites,
and the ability to synthesize extracellular polysaccharides [123,124]. Specifically,
glucosyltransferases (gtf) have been shown to be one of the major virulence factors in the
pathogenesis of dental caries [125,126].
Passive treatments administered topically [127,128], by local injection [129-131],
intranasally [132,133], and orally [134-138], specifc for S. mutans have all been
previously tried with varying degrees of success in both animal models and human trials.
The most direct evidence supporting the potential for S. mutans specific avian IgY
antibodies derives from the research of Michalek et al. and Filler et al [134,136].
Michalek et al. was able to show in an experimental animal model of dental caries that
oral administration of S. mutans- specific bovine milk antibodies was able to reduce
caries. In humans it was reported that those who used a mouth rinse with S. mutans
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bovine milk antibodies had an initial decrease in the number of recoverable S.mutans
[134].
To test the potential success of an avian IgY antibody passive treatment for dental
carries caused by S. mutans, Hatta et al. isolated avian IgY antibodies specific for the
whole bacteria. The S. mutans specific IgY was formulated into a mouth rinse to be used
by volunteers as a way to prevent S. mutans colonization in the mouth. Levels of S.
mutans decreased in volunteers who gargled with the S. mutans specific IgY mouth rinse
[139]. The presence of antibodies in the volunteers correlated with protection against
caries formation. It is likely that the polyclonal S. mutans specific IgY in the mouth rinse
had antibodies specific to the insoluble glucans covering the surface of the bacteria, and
less to the serotype-specific antigenic sites on the surface of S. mutans, Thus allowing the
potential to interact with the various seroptyes of the mutans streptococci that can exist in
human saliva and plaque [139].
Kruger et al. targeted the gtf virulence factor of S. mutans by developing anti-cellassociated (CA) gtf IgY antibodies from the egg yolk of chickens immunized with gtf.
Gtf is essential for the production of glucans by S. mutans and an important virulence
factor. S. mutans with defective glucan function induce markedly reduced levels of
smooth and sulcal surface carious lesions in rats [122]. These S. mutans- specific
chicken-derived anti-gtf antibodies were tested in desalivated rats to mimic clinical caries
situations in patients with reduced salivation (dry mouth) due to medication, Sjogren’s
syndrome, or other causes. Desalivated rats given drinking water containing the anti-CAGtf-IgY had significantly lower development of smooth surface and sulcal caries lesions
compared to rats given IgY control water and sterile water.
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Helicobacter pylori
Helicobacter pylori (H. pylori) infects over 50% of the population worldwide and
is the most important etiological agent of gastroduodenal ulcers and malignancies [140].
After oral ingestion of the bacteria, once in the gastrointestinal tract, H. pylori has
numerous virulence factors that help it to survive and cause disease, including the ability
to move via flagella. The bacteria are able to produce a cytotoxin, and have adhesins on
their surface to aid in attachment to epithelial cells. The urease enzyme produced by the
bacteria is one of the most important virulence factors that aids in the organism’s ability
to colonize gastroduodenal mucosa [141]. Urease is able to hydrolyze urea into carbon
dioxide and ammonia, permitting H. pylori to survive in the acidic environment of the
gastrointestinal tract [142,143]. H. pylori disruption of the epithelial layer in the
gastrointestinal tract causes various types of gastritis that can be indicative of further
clinical outcomes, including ulcers. H.pylori is responsible for the majority of duodenal
gastric ulcers. The lifetime risk of peptic ulcer development in persons infected with
H.pylori ranges from 3% in the United States, to 25% in Japan [144,145]. Eradication of
H. pylori drastically lowers the recurrence rates of H. pylori- associated ulcers [146].
The goal of current H. pylori treatment is to eliminate the organism. But, there are
several cases where anti-microbial agents do not work efficiently enough to clear the
infection and there is a potential for the development of resistant organisms. This leaves
the infected individual at risk for the recurrence of ulcers and continued pain. There is
still the need for H. pylori treatments that can be used alone or in conjunction with
current anti-microbial agents.
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A novel passive immunization treatment for the prevention and reduction of H.
pylori infections was created by Horie et al., utilizing current knowledge on the urease
virulence factor of the bacteria [140]. The cross-reactivity between the anti H. pylori
whole cell lysate antibodies, and other bacteria in the human gastrointestinal tract, can
decrease the efficacy of the anti IgY H. pylori treatment. This fact makes it necessary to
develop antibodies that target specific antigens of the bacteria. A H. pylori ureasespecific polyclonal chicken IgY antibody (IgY-urease) was isolated from the yolks of
eggs collected from hens immunized with an aqueous extraction of purified H. pylori
urease enzyme. A drinking yogurt was formulated containing 1% IgY-urease along with
Lactobacillus acidophilus and Bifidobacterium spp. [140]. The effectiveness of the IgYurease containing yogurt was tested in human volunteers who were positive for the
presence of H. pylori as determined by a urease breath test (UBT). The volunteers who
drank the yogurt with the IgY-urease had a significant reduction in UBT values compared
to controls, meaning the IgY-urease yogurt was effective at suppressing H. pylori
infection in individuals previously colonized with H. pylori [140].
Another avain IgY antibody treatment specific for H. pylori has been tested in
BALB/c mice. This treatment targets a highly immunoreactive and bacteria specific 58kDa antigen (Hp58) that was originally identified in the whole cell lysates of H. pylori
[147]. Polyclonal IgY was generated against the target by the immunization of White
Leghorn hens with purified Hp58. Eggs were collected and Hp58- specific IgY was
isolated from the egg yolk. IgY from non-immunized hens was used as a control. The
reactivity of IgY-HP58 antibody was tested by western blotting. The IgY-Hp58 antibody
identified the 58-kDa immunoreactive band in whole cell lysates of H. pylori using
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western blotting. There was no band present when egg yolk antibodies from nonimmunized hens (IgY-N) reacted with cell lysates [147]. To test the effectiveness of the
IgY-HP58 antibody against H.pylori infection, a mouse model of infection was used.
Mice were passively immunized with IgY-Hp58 antibodies at 1 day, 1 week, 4 weeks, or
12 weeks post infection with H. pylori. The highest effect of passive immunization was
achieved when the IgY- Hp58 was given 1 week after infection. There was a significant
difference in the degree of gastritis at this point, and a higher recovery rate when
compared to the IgY-N treated group [147]. Together, these results suggest that the IgYHp58 antibody is able to prevent H. pylori infection in the mouse model.
Salmonella
Salmonella enterica serovar Enteritidis (Salmonella ser. Enteritidis) and
Salmonella enterica serovar Typhimurium (Salmonella ser. Typhimurium) are the most
frequent serotypes of Salmonella to cause infection in humans and other animal species
[148-150]. Salmonella is a foodborne pathogen that can cause a variety of clinical
manifestations including minor gastroenteritis to a more serious bacteremia that appears
in about 8% of untreated cases [151]. Salmonella can also persist in the gastrointestinal
tract after symptoms have resolved, causing some individuals to become chronic carriers,
who are able to continue to spread bacteria unknowingly.
The first reported case of Salmonella resistant to a single antibiotic was in the
early 1960s [152]. Since then, the chances of isolating a resistant strain has continued to
increase. Salmonella has many surface components, which are important for the
bacteria’s virulence and which are ideal targets for passive antibody treatments. Passive
protection by egg yolk antibodies targeted against the many Salmonella surface
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antibodies serve as a potential method for the control of intestinal colonization by
Salmonella. One such surface antigen on Salmonella ser. Enteritidis, involved in the
pathogenesis of the bacteria, is the fimbria. Salmonella ser. Enteritidis has been shown to
produce three types of fimbria, referred to as SEF 14, 21, and 17 [153-155], which are
correlated with bacterial virulence [156-159], and bacterial adherence to mucosal
epithelium.
To better understand the role of fimbriae in Salmonella ser. Enteritidis
pathogenicity, and the potential for protection of egg yolk IgY antibodies, SEF-14
specific IgY antibodies were isolated from the egg yolk of chickens immunized with
purified SEF-14. Western blotting confirmed the specificity of the SEF-14 IgY
antibodies by the presence of a single immunoreactive band at 14-kDa, after the
membrane-bound surface proteins of Salmonella ser. Enteritidis were electrophoretically
transferred to a nitrocellulose membrane [160]. To evaluate the clinical potential of SEF14 IgY antibodies, mice were challenged with Salmonella ser. Enteritidis and treated with
the SEF-14 IgY antibody. The SEF-14 IgY antibody dose dependently increased the
survival rate of mice treated after challenge with Salmonella ser. Enteritidis, compared to
control mice treated with avain IgY antibody from non-immunized hens. Mice treated
with the highest titer of SEF-14 IgY antibody had the greatest survival rate at 77%. The
lower antibody titer treatment group had a 59.3% survival rate, and the control group had
a 32% survival rate [160]. The difference in survival rate between the high antibody titer
treatment group and the control group was significant [160]. The Salmonella ser.
Enteritidis infected mice did not develop any overt symptoms of diarrheal disease, but in
the mice that had the infection, the challenge bacterial strain was isolated from the liver,
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spleen, kidney, and small intestines. In mice that survived infection because of the
antibody treatment, only a few harbored any bacteria in the organs listed above.
In vitro, the SEF-14 IgY antibodies were able to reduce the adherence of
Salmonella ser. Enteritidis to isolated murine small intestinal cells, compared to control
antibodies. The exact mechanism that allows the SEF-14 IgY antibody to increase
survival is unknown; the in vitro results and lack of bacteria in the organs after antibody
treatment, point towards the SEF-14 IgY antibodies being able to inhibit the initial
attachment of the bacterial to cell surfaces, and, potentially, the next steps of tissue
invasion. The prevention of bacterial adhesion is a phenomenon that has been observed
by others studying the effects of Salmonella specific IgY antibodies. In vitro, IgY
antibodies specific for the LPS of Salmonella ser. Typhimurium and Salmonella ser.
Enteritidis have been reported to inhibit Salmonella adhesion and to prevent disease
[161]. Chalgohoumi et al. created IgY antibodies specific for the outer membrane
(OMP) of Salmonella ser. Typhimurium and Salmonella ser. Enteritidis. The OMPspecific IgY was able to prevent Salmonella adhesion in a concentration dependent
manner, along with inhibiting bacterial growth [162].
Yokoyama et al. determined the treatment potential of avian IgY antibodies
specific for the OMP, lipopolysaccharide (LPS), and flagella (fla) of Salmonella ser.
Enteritidis and Salmonella ser. Typhimurium[150]. The OMPs are exposed on the
surface of the bacterial cells where they can easily interact with antibodies [163]. There
is increasing evidence that motility facilitated by the flagella increases the probability the
bacteria will reach a suitable site for invasion, an important part of causing an infection
for the bacteria [164,165]. The importance of these three cellular structures in bacterial
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pathogenesis and their surface exposure makes them ideal targets for antibody treatments.
Avian IgY antibodies specific to the OMP, LPS, and Fla of both Salmonella ser.
Enteritidis and Salmonella ser. Tyhimurium were made by immunization of five month
old White leghorn chickens with OMP, LPS, or FLA from the two bacteria strains.
Avian IgY antibodies specific to the six antigen targets were then isolated from the eggs
of immunized chickens. Control antibodies were isolated from the eggs of nonimmunized chickens to test the efficacy of the Salmonella specific IgY. Mice were
challenged with either Salmonella ser. Enteritidis or Salmonella ser. Typhimurium and
then orally treated with either OMP-, LPS-, or Fla- IgY specific to the bacteria they were
challgenged with. The antibody treatment continued three times a day for three
consecutive days. For mice challenged with Salmonella ser. Enteritidis treatment with
OMP-IgY resulted in 80% surivial, 47% survival with LPS-IgY, and 60% survival with
Fla-IgY; survival for the control IgY treated mice was only 20% [150]. The difference in
survival between the OMP-IgY treated group and the control group was significant.
There was a similar trend in results for the mice challenged with Salmonella ser.
Typhimurium. The group of mice treated with OMP-IgY had 40% survival, LPS- IgY
30% survival, and Fla- IgY 20% survival; all of the mice in the control group died [150].
Lee et al. developed avian IgY antibodies specific for Salmonella ser. Enteriditis
and Salmonella ser. Typhimurium, but the aim of their research was to gain a better
understanding of IgY antibody specificity and how the IgY antibody interacts with the
bacteria. The IgY antibodies used in their research was specific for whole cell bacteria.
There was cross reactivity between the two antibodies, but ultimately both types of
Salmonella-specific IgY antibodies were found to inhibit growth of homologous
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Salmonella in liquid medium [54]. They were unable to find out the exact mechanism of
growth inhibition, but there were structural changes to the surface of Salmonella where
IgY bound [56]. The above mentioned research in the area of avian IgY antibody
treatments for Salmonella has the potential to be transferred into humans to be used
clinically to treat salmonellosis caused by food poisoning.
Escherichia coli
Enterotoxigenic Escherichia coli (ETEC) causes enteric colibacillosis, severe
watery diarrhea, in newborn (suckling) calves, and suckling as well as weaned pigs, but is
rare and essentially non-existent as a cause of illness in other farm animals. In humans
ETEC is recognized as one of the most frequent causes of childhood diarrhea in
developing countries and an important causative agent of traveler’s diarrhea [166,167].
The similarities in prevalence and severity of disease between humans and animal cases
of ETEC provide researchers a chance to understand human ETEC infection through the
use of animal models. ETEC bacteria are known to adhere to the small intestinal
epithelium without inducing significant morphological changes and secrete enterotoxins
that alter the functions of enterocytes by increasing secretion and reducing absorption
[168]. Because of the importance of adhesion in the pathogenic process of ETEC,
adhesins on the surface of fimbriae or pili are essential virulence factors. The fimbriae of
animal ETEC are K88, K99, K987P, Fy.Att25, F41, and F18 [169]. Potentially
pathogenic E. coli are found in the intestinal tract and feces of many healthy animals.
Continuous birthing and poor sanitary conditions often lead to ETEC infections in
offspring. Infectious ETEC on the skin and mammary glands of mothers can easily be
ingested by offspring.
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Treatment of ETEC infections can start with prevention of the infection all
together, by building up the immunity of adult female cows and pigs through vaccination.
If it is necessary to treat ETEC- infected offspring, antimicrobial treatments are often
used. Usually, if one offspring in the litter is infected all in the litter will have to be
treated. Because of which, the chances of the infection spreading through the herd are
high.
Avian IgY antibody treatments of ETEC infections in animals are an attractive
option because it would reduce the use of antibiotic treatments in livestock. An avian
IgY antibody treatment would only persist in the animal long enough to help clear the
infection, and would not have any long term effects in pigs or calves used as a food
source. Oral administration of antibodies derived from serum and colostrum and even
monoclonal antibodies have been very successful treatments; however, it is expensive to
obtain the large amounts of antibodies required [170]. A cost effective source of
antibodies to treat ETEC is avian IgY antibodies, specifically egg yolk antibodies from
immunized chickens. There are several researchers that have used animal models of
ETEC infection to evaluate the potential of ETEC- specific IgY antibodies. A main
target for these IgY antibodies are the bacteria’s adhesins most likely due to the role they
play in bacterial pathogenesis. Yokoyama et al. used a porcine model of ETEC infection
to assess the treatment potential of avian IgY antibodies specific for fimbriae adhesins
K88, K99, and K987P. The adhesion- specific antibodies were isolated from the egg
yolks of E.coli frimbrial immunized chickens. In vitro the presence of anti-adhesin IgY
prevented the adhererence of K88+, K99+, and K987P+ E.coli strains to isolated procine
small intestine epithelial cells [171]. There was no cross-inhibition between the three
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types of antibodies used. Similar results were obtained in vivo in control piglets. In
control animals, adhering E.coli could be observed along with whole length of the small
intestines, whereas there was no adherent E.coli along the intestinal epithelial surface of
piglets treated with E.coli fimbriae- specific IgY [171].
In another experimental design, Marquardt et al. isolated polyclonal IgY
antibodies from the egg yolks of chickens immunized with purified K88 fimbrial antigen
from a local strain of ETEC (E.coli K88+ MB, Manitboa, Canada)[172]. The egg yolk
antibodies were freeze dried and made into a powder to be tested in a porcine model of
ETEC. Piglets or neonatal pigs were challenged with K88+ MB orally and then orally
treated with K88 MB- specific IgY antibodies or control non-specific IgY antibody
powder at various time points post-challenge. K88 MB- specific IgY antibody treatment
was able to protect both neonatal and 21 day old weaned piglets from diarrhea induced by
the challenge. In piglets challenged and treated with K88 MB specific IgY antibodies,
diarrhea was cured within 24 hours after treatment, whereas the piglets treated with the
control IgY antibodies continued to have diarrhea during the entire duration of the
experiment, resulting in 62.5% death [172]. Not only was the occurrence of diarrhea
decreased in the neonates and piglets treated with K88 MB- specific IgY antibodies, but
mortality was also significantly decreased.
Further research using the K88 MB specific IgY antibody was completed,
studying the potential of the antibody to inhibit in vitro adhesion of K88+ E.coli to piglet
intestinal mucus. The effectiveness of the chicken IgY antibodies for inhibiting adhesion
of ETEC to mucus in this study was influenced by two factors: dose of antibody, and
concentration of ETEC. K88 MB- specific IgY antibody, when diluted 50-100 fold, was
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able to strongly inhibit adhesion of K88+ E.coli at a concetnraion of 109 CFU mL-1
(adhesion was <6%) [173]. However, if the antibody was diluted 100 times it was unable
to prevent adhesion of E.coli. These results correspond with the previous dose-dependent
results of Marquardt et al. and others. There were limits to what the K88 MB- specific
IgY antibodies were capable of; the antibodies were unable to displace K88+ MB E.coli
once it was already bound to the receptor in the mucus. Also, when the IgY antibodies
and K88+ MB E.coli were incubated together, prior to exposure to immobilized mucus,
there was no difference in inhibition of adherence between K88 MB- specific IgY
antibodies and control IgY antibodies [173]. For this specific application of the IgY
antibody a prophylactic treatment approach would probably be more advantageous.
As was previously mentioned, ETEC is a major cause of diarrhea and death in
neonatal calves [174-176]. The K99 pilus is one of the adherence factors found on ETEC
isolated from neonatal calves [177-180]. As a potential alternative to current treatment
methods for ETEC in calves, Ikemori et al. developed a pilus- specific IgY antibody
powder[180]. Newborn colostrum-fed calves were used as the model of ETEC infection
[180]. Calves were challenged with ETEC and then treated with either pilus- specific
IgY antibody powder in milk, or non-specific IgY antibody powder in milk at varying
titers. Calves in the control group developed severe diarrhea and died on day three post
challenge. The opposite was true of calves treated with pilus IgY antibody powder. The
calves in the higher titer groups (1:800 and 1:1600) all recovered from disease; diarrhea
was temporary, and was not accompanied by dehydration or weight loss [180]. Calves in
the lowest antibody titer group (1:200) did experience diarrhea and weight loss. These
results again support the dose-dependent effects of ETEC specific IgY antibodies.
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Rotavirus
Rotavirus is a key enteric pathogen in infants and young children. Each year
rotavirus causes millions of cases of diarrhea in children. Almost 2 million cases will end
up in the hospital [181], and an estimated 453,000 will result in the death of children
under the age of 5 [182], 85% of whom live in a developing country [183]. Recently two
vaccines have been approved for use against rotavirus. One downfall is the vaccines’ low
protection efficacy in children from African and Asian countries [184,185], the two
countries that contain areas where children are at high risk for infection. Vaccination is
an effective method of controlling disease in developed countries because of wellestablished health systems. But, in developing countries, the outcome is much different.
Approximately 1.76 million children die each year from gastroenteritis in developing
countries [186], many of which are due to rotavirus [183], as indicated above. In addition
to vaccines against rotavirus there needs to be an easy-to-administer and cost-effective
treatment for rotavirus. An antibody-based passive treatment is an ideal alternative
approach to prevent and treat rotavirus infections.
Several in vitro studies have proven the potential use of rotavirus specific IgY
antibodies for treatment of rotavirus infections [187-190]. In the second human trial,
children with proven rotavirus diarrhea were treated with anti-rotavirus IgY antibiodies
isolated from the eggs of human rotavirus immunized hens. There was a trend towards
lower daily and cumulative stool output, compared to children treated with control IgY
antibodies, however the daily and cumulative stool output difference was not significant.
Probability of clearance of rotavirus from stool of children treated with anti-rotavirus IgY
antibodies was significantly higher compared to the control treated children. At day four
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post-treatment, 74% of children treated with anti-rotavirus IgY antibodies no longer had
detectable rotavirus in their stool, while more than 50% of children in the control IgY
antibody treatment group still had rotavirus in their stool at this point [191]. One
explanation for only one significant set of data in this research could be the relatively low
dose of anti-rotavirus IgY antibodies that was used.
To gain insight into the dose of the efficacy of anti-rotavirus IgY antibodies, an
animal model of rotavirus infection was used, which allowed for higher doses of antirotavirus IgY antibodies to be given. The same anti-rotavirus IgY antibodies that were
used in the clinical trials by Sarker et al. were also used in these experiments [191]. Four
day old mouse pups were challenged with Rhesus rotavirus. Twenty-four hours after
challenge, mice were treated with one of the four following doses of anti-rotavirus IgY
antibodies: 0.01 mg/mL 0.1mg/mL, 1.0 mg/mL, or 10.0 mg/mL. A significant difference
in prevalence of diarrhea was reported for mice treated with doses of 1.0 or 10.0 mg/mL
of anti-rotavirus IgY antibodies compared to control, 33% vs. 67% and 6% vs 67%,
respectively [192]. At lower doses there was no significant difference for this parameter.
The duration of diarrhea was reduced with anti-rotavirus IgY antibody treatment, and,
again, larger doses caused the strongest reduction compared to the control, with a
significant difference [192]. These results support the results of other studies: treatment
with anti-rotavirus IgY antibody is dose dependent. It is also possible, based on these
results, that using a higher dose of anti-rotavirus IgY antibody in the previous clinical
trial would have given a better outcome, especially considering the highest dose provided
the best protection.
Venoms
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Envenomation, due to snakebites and other venomous animals, is an often a
neglected public health issue affecting many individuals in underdeveloped countries,
specifically rural and tropical Africa, Asia, and Latin America [193]. While true,
individuals in developed countries are most at risk for envenomation during recreational
activities. A recent study estimates that at least 421,000 envenomings, and 20,000 deaths
occur worldwide from snakebites each year [193], and an estimated 1.2 million scorpion
stings occur each year, leading to 3,250 deaths [194]. Scorpion and snake venoms are a
complex mixture of peptides, enzymes, and other factors that cause a wide variety of
physiological reactions. Hyaluronidase, for example, is an enzyme present in all snake
venoms that aids in the spread of other venom components throughout the prey’s tissue
[195]. Snake and scorpion anti-venoms are most often derived from horse sera. Purified
anti-venoms often contain large amounts of non-specific serum proteins that can cause
side effects, some of which can be severe [196-198]. Side effects can range from serum
sickness, occurring in up to 80% of all patients treated with the current North American
rattlesnake anti-venoms [199,200], to the more severe anaphylactic reactions. These
reactions are in part due to the impurity of the anti-venoms and the reactivity of the antivenom immunoglobulins with human immune cells [199,201]. Treatment is further
complicated by the many unknowns involved, such as the amount of venom injected by
each poisonous animal. The lack of standardization in venom causes the amount of active
ingredients in commercially available North American anti-venom treatments to vary. In
an attempt to circumvent the unwanted reactions between anti-venom immunoglobulins
and components of the human immune system, avian IgY- specific antibodies for snake
venom were developed.
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Some of the first anti-venom IgY antibodies were made by immunizing chickens
with either a mixture of Cortalid snake venom or Leiurus quinquestiratus hebraeus
scorpion venom. Anti-venom IgY antibody was isolated from the egg yolks of the
immunized hens with each respective venom and affinity purified. The neutralizing
potential of the anti-venom IgY antibodies against both types of venoms was tested by
mixing the anti-venom IgY antibodies with the minimum lethal dose of each venom,
respectively, and injected into mice; the mice were then monitored for death. All ten
mice survived the 24 hour observation period when treated with the anti-Cortalid IgY
antibodies and only one out of nine mice survived without the anti-venom IgY antibodies
[202]. Results were similar for the anti- Leiurus quinquestiratus hebraeus IgY
antibodies. When mice were injected with Leiurus quinquestiratus hebraeus venom preincubated with anti-venom IgY antibodies, seven out of eight mice survived, and only
one out of six mice survived injection without anti-venom IgY antibodies [202]. Both the
snake and scorpion anti-venom IgY antibodies were able to neutralize the toxins present
in their respective venoms.
Similarly, IgY antibodies specific for the venom of snakes within the Bothrops
and Crotalus genera were developed through immunization of chickens with mixtures of
venoms from snakes within each genus. Venom- specific IgY was present in the serum
of hens just two weeks after immunization. Eggs were collected from the immunized
hens and IgY isolated from the yolks of the eggs that was snake venom specific. One
snake venom component is phospholipase A2 (PLA2 ), which causes inflammation. This
is caused by liberation of archadonic acid, a precursor of prostaglandins and leukotrienes
from the cell membranes [203]. In vitro, anti-venom IgY specific for venom from both
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genera of snakes was able to inhibit the activity of PLA2 in a dose- dependent manner
[204]. Both venom- specific IgY were also able to neutralize the lethal toxicity of the
venom as assessed by an in vitro-in vivo assay [204].
In two independent studies, Meenatchisundaram et al. studied the neutralizing
ability of venom- specific IgY antibodies against the venom from four different snakes
that are a common cause of human envenomation; the Naja naja (cobra), Bungarus
caeruleus (krait), Vipera ruseeli (Russell’s viper), and Echis carinatus (Saw-scaled viper)
[205,206]. The neutralizing ability of the venom- specific IgY antibody was assessed
through comparison of PLA2 activity, edema formation, and procoagulant activity in antivenom IgY antibody treated and control treated groups of mice. Anti-venom IgY
antibodies made against all four venoms inhibited PLA2 activity, decreased edema
formation, and neutralized procoagulant activity compared to controls [205,206]. These
results support the possible neutralizing potential that these anti-venom IgY antibodies
have in future in vivo studies and in humans.
Others
Avian IgY antibodies have been developed against other targets such as the
cytokines IL-1β and TNF. Allergic asthma has been shown to be successfully treated
with mammalian antibodies specific for the cytokine TNF-α [207-209]. However, further
studies with the anti-TNF-α antibodies identified the unfavorable risks associated with
long-term use of these treatments [210]. Another cytokine, IL-1β, is an important
proinflammatory cytokine involved in the progression of allergic asthma, contributing to
the formation of inflammatory responses within the airway [211]. Targeting of IL-1β by
anti-IL-1β IgY represents an alternative treatment option for allergic asthma.
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Wei-xu et al. used a hamster model of allergic asthma induced by ovalbumin
(OVA) to test anti-IL-1β IgY antibodies isolated from the eggs of laying hens immunized
with human recombinant IL-1β [212]. Allergic asthma hamsters were treated with either
saline alone as a control, anti-IL-1β IgY antibodies, or budesonide as a positive control.
There was decreased tissue damage in the lungs of hamsters treated with anti-IL-1β IgY
antibodies compared to control. There was no significant difference in the pathological
damage between the animals treated with budesonide and those treated with anti-IL-1β
IgY antibodies [212]. Along with preventing tissue damage, there was a significant
decrease in the numbers of eosinophils, neutrophils, and lymphocytes along with a
reduction in IL-1β, IL-4, IL-8, IL-13, TNF-α, TGF-β, and IgE in the peripheral blood as
well as bronchial alveolar lavage fluid [212].
IgY specific TNF-α antibodies have been developed for treatment of Chron’s
disease and ulcerative colitis as a potential alternative to current treatments. Current
treatments include immunosuppressants, corticosteroids, and antibiotics, all of which
come with limitations and side effects that can limit the efficacy of the treatments [213].
TNF-α is a key early mediator in these two diseases along with many others [214]. Other
drugs have been made against TNF-α, but they can be costly, result in multiple trips to
the medical provider for patients, and have adverse side effects. Anti-TNF IgY
antibodies were developed and tested in a rodent model of inflammatory bowel (IBD) as
a way to better treat TNF-α influenced diseases. The anti-TNF IgY was able to
effectively treat IBD in mice when administered both prophylactically and
therapeutically, and was effective against both the acute and chronic phase of colitis in
the animal model [215].
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West Nile Virus
Previous research in the Bradley lab at the University of North Dakota has been
done with the immune serum from geese and purified goose IgY antibodies. Initial
studies were done to determine if serum from West Nile Virus (WNV) immune geese
could prevent or treat infection. Geese were treated with immune serum either prior to
WNV infection or after WNV Infection. There were approximately 10,000 geese in each
study, which showed a marked decrease in the mortality for both groups. More
specifically, there was approximately a 65% reduction in mortality when used as a
pretreatment and an approximate 62% reduction in mortality when used therapeutically
(unpublished results Schiltz, Petell, and Bradley). Similar results were seen with purified
WNV- specific goose IgY antibodies.
The effectiveness of the WNV-specific IgY antibodies were then tested during
WNV infection in WNV-infected Golden hamsters. WNV-specific IgY antibody
treatment resulted in both mortality and viral titers of zero. Comparatively, sham treated
hamsters had a mortality rate of 100% and 65% (unpublished results Schiltz, Petell, and
Bradley). This research demonstrated that the goose antibodies were able to protect
mammalian subjects against infection.
Overview of IgY
In summary, avian IgY antibodies are functionally similar to mammalian IgG
homologs, but have sufficiently distinct structural characteristics. This difference is what
makes the use of avian IgY antibodies an attractive alternative for passive immunizations
for mammals, specifically, in various diseases and infections in humans. Discussed
below is our research focused on investigating the ability of goose IgY antibodies to

43

ameliorate two human pathogens: Dengue virus type 2 and Andes virus. Andes virusspecific goose IgY antibody treatments that were developed include antibodies that
recognize unique epitopes in comparison to virus specific mammalian IgG antibodies.
The structural differences in IgY antibodies, compared to mammalian IgG, results in IgY
antibodies inducing less of an inflammatory response than what can be detected with
mammalian IgG antibody therapies. Discussed next are the general safety studies
demonstrating the potential to utilize avian IgY antibodies in therapeutic application for
mammalian disease.
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CHAPTER II
DEVELOPMENT OF GOOSE MONOCLONAL IGY ANTIBODIES FOR
TREATMENT OF DENGUE VIRUS TYPE 2 INFECTIONS

Introduction
History of Dengue Virus in Humans
The World Health Organization estimates that 50 to 200 million dengue virus
(DENV) infections occur each year [216]. However, newer research estimates these
numbers to be closer to 390 million cases per year, 96 million of which will lead to
clinical manifestations of varying severity [217]. DENV is currently regarded as the
most important arboviral disease internationally because over 50% of the world’s
population live in areas where they are at risk of infection, and approximately 50% of
people live in DENV endemic countries [218-222].
DENV is a member of the Flaviviridae family of RNA viruses. There are four
antigentically distinct serotypes of the DENV (DENV-1, DENV-2, DENV-3, and DENV4) differing at the amino acid level by 25-40% [223]. Genetic studies of the four DENV
have provided evidence that the four viruses evolved from a common ancestor that
circulated between non-human primates and mosquitoes, approximately 500 years ago,
with all four virus serotypes emerging separately into a human urban transmission cycle
[224]. DENV is primarily transmitted to humans by mosquitoes from the genus Aedes,
primarily the Aedes aegypti (A. aegypti) species, and also the Aedes albopictus species in
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some geographical areas. Mosquitoes become infected after taking a blood meal from an
infected human. After the blood meal, the virus travels into the mosquitos’ midgut and
continues on to infect other tissues of the mosquito. Ultimately, to infect humans, the
virus needs to travel to the salivary glands of the mosquito and be shed in the saliva of the
mosquito while taking a blood meal [225]. The A. aegypti mosquito is a very efficient
vector; it has a high affinity for human blood, is adapted to urban living, and it likes to
breed in and around houses in water containing vessels [226].
The geographical spread of the virus is primarily in tropical and subtropical
countries currenlty. DENV disease awareness increased after the end of World War II,
but the disease has a much longer history of interaction with humans dating back to
China between 265-420 A.D. [227]. The first two modern cases of DENV infection led
to the isolation of DENV-1 in 1943, from Japan and DENV-2 in 1945, from Hawaii
[228]. After these two cases, epidemics of DENV began to spread to more of the tropical
regions of the world. This was facilitated by the spread of the mosquito at the end of
World War II and was accelerated by urbanization and globalization; including
increasing international travel not only of people, but also goods in which mosquitoes
harboring the virus can survive [218]. The increased prevalence of DENV was further
facilitated by inadequate housing, poor water systems, and improper sewer and waste
management systems causing A. Aegypti levels to reach increasingly high densities.
In the 1960s, there was a dramatic surge in DENV activity in many tropical
locations throughout the world [229-232]. Increased disease severity was associated with
these epidemics due to the overlapping spread of the four DENV serotypes, referred to as
hyperendemicity [233-235]. Research in hyperendemic areas looking at secondary
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heterotypic DENV infections led to the development of the antibody dependent
enhancement (ADE) theory of pathogenesis [236]. In the 1970s, only nine countries had
reported severe DENV cases; that number has since quadrupled [221]. This is, in part,
due to multiple DENV serotypes circulating in the same geographic area. Until the
1980s, a majority of the endemic areas had only reported one or two types of DENV.
Now all four DENV serotypes are circulating in Asia, Africa, and the Americas
[227,237].
As this brief history of DENV demonstrates, the spread of the virus is ultimately
connected to the spread of its mosquito vector, which is in turn influenced by changes in
the climate, globalization, and travel. Moving into the future these variables will
continue to change and so will the geographic spread of the virus into non-endemic areas
and, as the four DENV serotypes continue to circulate, more hyperendemic areas will be
created. All of which will contine to increase the chances of secondary heterotypic
infections increasing patient’s chances of severe DENV infection.
Spread of DENV to the Americas was delayed by an A. aegypti mosquito control
campaign initiated by the Pan American Health Organization. The primary goal of the
program was to control the spread of yellow fever, but also happened to control the
spread of DENV. This prevented the spread of DENV to the Americas for 20 years, until
the program was discontinued in the late 1970s [218,226,238]. In the 1980s, the number
of DENV cases began to rebound and by 1995 the A. aegypti mosquito was reintroduced
into the Americas, and its geographic distribution spread to include Asia, and continues
to spread to this day [222,226]. The first indigenous case of DENV in the United States
since 1945, was reported in Brownsville, Texas in 1980. DENV-1 was isolated from a 5-
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year-old girl that did not have a history of traveling outside of Brownsville. An
additional 63 DENV-1 cases were confirmed in Texas in 1980, 52 of these cases were in
counties located near the Mexico-Texas boarder [239]. More recently in 2005,
autochthonous DHF was reported in a woman in Texas, and 25 additional cases of DENV
infections were reported in Brownsville, Texas, of which at least three were locally
acquired [240]. Between 2009 and 2012, a total of 103 autochthonous DENV cases were
reported in Florida [241,242]. Testing of mosquitoes in the area detected the presence of
DENV-1 in A. aegypti mosquitoes [243]. Previously, people living in the United States
only have to be concerned about DENV infections, when traveling to areas where the
virus was endemic, but now the mosquito vector has spread such that infections of DENV
can be acquired within the continental United States.
DENV Structure
DENV is a small, enveloped virus with a single-stranded, positive-polarity RNA
genome of 10.7kb [244]. The 10.7kb genome is translated as a single polyprotein and
then cleaved into three structural proteins (capsid [C], premembrane/membrane [prM/M],
and envelope [E]) and seven nonstructural (NS) proteins, (NS1, 2A, 2B, 3, 4A, 4B and 5)
by host and viral proteases [245-247]. DENV primarily infects cells of the monocytemacrophage lineage, liver, and endothelial cell linings of blood vessels [248-250]. The
first cells to be infected with DENV are typically tissue resident Langerhans cells in the
skin, due to their close proximity to the mosquito bite and virus entering the host. E
protein on the surface of the virus interacts with receptors on the host cell surface. It is
unknown which receptor(s) on host cells facilitate the entry of DENV; one possible
receptor is DC-SIGN [251]. Once in the cell, the acidic environment of the endosome
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triggers a structural change in the E protein, which results in fusion of the viral, and cell
membranes [252,253]. The virus nucleocapsid is released into the cell cytoplasm, the
viral RNA and the capsid protein can then dissociate. Initially the viral RNA genome is
translated into a single polyprotein that is then co- and post-translationally cleaved into
the appropriate proteins. During translation, structural proteins are translocated and
anchored in the ER by various signal sequences and membrane anchor domains. After
appropriate cleavages the capsid protein and viral RNA localize in the cytoplasm, the
capsid protein remains associated with ER, and the prM and E proteins form
heterodimers on the lumenal side of the ER [254-256]. After the initial round of
translation, viral replication begins.
Replication is carried out by the NS5 protein, which functions as a RNA
dependent, RNA polymerase along with help from a viral helicase and other unidentified
proteins [257]. At the start of replication the positive stranded RNA genome is first
transcribed into a complementary negative-strand RNA, this results in a double-stranded
RNA (dsRNA) intermediate [258]. The negative strand of the dsRNA continues on to
serve as the template for any positive-strand RNA that is made. Viral RNA synthesis is
asymmetric, meaning ten times more positive-strand RNA is made than negative-strand.
Positive-strand RNA can serve as the viral genome or enter another translation cycle,
while all negative-strand RNA exists only as part of the dsRNA intermediate [259]. Viral
components then come together for assembly of viral particles. Initially, immature virus
particles are assembled in the lumen of the ER. These viral particles are immature
because they are unable to facilitate host-cell membrane fusion due to the fact that the
surface of the virus has an icosahedral arrangement with 60 trimeric spikes, each made up
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of prM heterodimer with the prM protein positioned at the tip of each E protein trimer
[246,260-262]. The immature virus particles are transported through the trans-Golgi
network where they will mature into infectious virions. In the low pH of the trans-Golgi
network the pr peptide is cleaved from the M protein by the host protease furin. The 60
timers of prM-E then dissociate to reform as 90 anti-parallel E protein homodimers which
lie flat on the surface of the mature virion [245,252,263,264]. The mature virion is then
released from the host cell by exocytosis [252].
DENV Immunopathogenesis
The pathogenesis of DENV relies on the interplay between the virus and host
factors that result in a variety of clinical manifestations. Clinical disease caused by
DENV infections can range from an asymptomatic infection in some individuals, to mild
dengue fever (DF), or the more severe dengue hemorrhagic fever (DHF)/dengue shock
syndrome (DSS). Most primary DENV infections in patients over the age of one year old
manifest as either asymptomatic or DF. During the primary DENV infection, lifelong
immunity is established in the individual against the infecting DENV serotype [265,266].
During subsequent infections with heterotypic DENV serotypes individuals are at a 15-80
times greater risk for developing the more severe DHF; 90% of all cases of DHF occur
during secondary heterotypic DENV infections [267]. The increase in severity of the
secondary infection is dependent, in part, on ADE [227,268-270].
ADE is caused by cross-reactive or sub-neutralizing antibodies binding to the
virus, forming immune complexes. The complexes utilize their Fcγ receptor (FcγR)
binding to bind cells, facilitating virus entry into cells and triggering inflammation and
associated shock-like symptoms [267,269,271,272]. There are a small number of severe
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DHF cases in primary DENV infections, most of which are often transmitted to infants
born to DENV-immune mothers [273]. It is thought that children born to DENV-immune
mothers are protected against DENV by antibodies transferred from the mother during
the first three to four months after birth. Following those first few months, the
neutralizing ability of the antibodies declines and become non-neutralizing, which
actually enhancing the chances of infection until about the age of one. At age one, the
maternal antibody levels are cleared from the child and no longer pose a risk [227,274276].
The majority of DENV infections are asymptomatic, but for those who develop a
symptomatic infection, the incubation period can range from three to fourteen days, and
typically span four to seven days [265,277-280]. The majority of individuals with
symptomatic DENV infections develop DF, which most commonly presents as a sudden
onset of fever lasting two to seven days. Accompanying the fever is a severe headache,
pain behind the eyes, generalized myalgia and arthralgia, rash, anorexia, abdominal pain,
and nausea [281,282]. DF is typically milder in younger children compared with older
children and adults [268,273,280]. Common laboratory abnormalities seen in DF patients
are leukopenia, thrombocytopenia, and elevation in serum transaminases [273,283-285].
Most patients recover from DF fully without any lasting chronic symptoms or
complications within a week after the onset of disease [286]. Some atypical clinical
features of DENV infections include encephalitis, myocarditis, hepatitis, pancreatitis, and
acute respiratory distress syndrome. The atypical manifestations are most likely due to
disease pathology at different endothelial surfaces [287-291]. The more severe forms of
DENV infection, DHF and DSS, begin with the same clinical symptoms as DF, but then
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progress to include hemorrhaging and increased vascular permeability due to the viral
infection. Viremia in DHF/DSS is generally 10-to-100 fold higher than in DF [292]. As
was noted above, DHF/DSS is most often seen in secondary heterotypic DENV
infections and is therefore more common in areas where all four DENV serotypes are
circulating [221]. Four to five days after the onset of DF-like symptoms, DHF patients
usually show a decline in their fever and shortly thereafter the patient’s condition begins
to deteriorate, starting with a narrowing of the pulse pressure. Patients then typically
become hypotensive due to plasma leakage, and there may hemorrhagic manifestation
[266]. The DSS stage is entered at the onset of increased vascular permeability, resulting
in a loss of plasma fluids into the interstitial spaces, so much so that cardiac output is
compromised resulting in hypovolemic shock [293]. The shock stage is short in duration
but life threatening and within 24 hours patients will either survive or succumb to the
infection [294].
The World Health Organization (WHO) categorizes DHF/DSS into four grades
based on severity, from the less severe (grade 1) to the more severe (grade 4). If patients
progress to DSS they are categorize in either grades 3 or 4 [216]. Unfortunately, only
supportive treatment is available for DF, DHF and DSS patients. Currently there are no
antiviral treatments available for DENV in general, and vaccine development has been
challenged by the requirement to protect against the four serotypes to prevent ADE.
Presently, the only way to prevent DENV infections is to control to the mosquito vector.
Immune Response to DENV
Humoral and cellular immunity both play a role in the protection and clearance of
DENV infections. During a primary DENV infections, these two branches of the
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immune response are able limit most infections of milder DF, and allow for the
development of immunological memory that can protect the individual against
subsequent infections with that DENV serotype. In contrast, during secondary
heterotypic DENV infections the memory immune cells from the previous infection
generate a less than ideal immune response against the virus. This enhances the infection
and often times causes a more severe DHF/DSS reaction.
During a primary infection, DENV enters the skin and is processed by
Langerhans cells and immature dendritic cells (iDC) present in the dermis. The
Langerhans cells, and other immune cells in the area, are activated to release IFN-γ and
other cytokines. The iDCs then travel to the lymph node where they mature and play a
part in initiating the cellular and humoral immune responses through interactions with
CD4+ and CD8+ T-cells. During a primary DENV infection, cytolytic effects of CD8+ Tcells are important in the host’s defense against the virus [295]. The T-cells also produce
IFN-γ and TNF-α, which augment the anti-viral response. CD4+ T-cells can go on to
activate B-cells to produce IgM followed by IgG, predominantly subclasses IgG1 and
IgG3 [296]. At this stage of infection, the humoral response may also play a role in
controlling the infection. IgM antibodies are typically the first antibody isotype present
after infection, detectable three to five days after illness in 50% of patients, increasing to
93-99% of patients after six to ten days of illness [227]. The DENV-specific IgM levels
usually peak two weeks after the onset of fever and then decline over the next two to
three months [221,297-299]; virus specific IgG is detectable in patients after the first
week of illness and then continues to increase [227]. After the virus leaves the skin it can
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travel through the blood to infect other tissues and tissue macrophages, especially those
in the liver and spleen [250].
In a secondary heterotypic DENV infection, patients are at an increased risk of
developing DHF/DSS; pre-existing immunity from a previous DENV infection, age, and
time between infections, are each primary risk factors. The exact pathogenesis of
DHF/DSS is still poorly understood, but there are two known contributing immune
factors: ADE [227,268-270,300] and original antigenic sin (OAS) [301,302].
In ADE antibodies from the primary DENV infection remain active, but are nonor sub-neutralizing against the DENV serotype causing the current infection. These
antibodies bind to the virus, forming antibody-virus complexes that gain access into FcγR
bearing cells via the Fc portion of the antibody [266,267,269,271,272]. This increases
the number of DCs and monocytes/macrophages that are infected in the blood of
DHF/DSS patients increasing the viral load in patients, immune activation of the cells,
and cytokine release [292]. Antibody-antigen complexes also have the potential to
activate the complement pathway, leading to temporal plasma leakage [303,304]. There is
a 10- to 100-fold greater level of virus in the blood of DHF/DSS patients compared to DF
patients [292].
OAS is the second proposed contributing factor to DHF/DSS. During a
secondary heterotypic DENV infection, memory T-cells from the previous DENV
infection are re-activated. As a result the T-cell response is directed against the DENV
serotype from the primary infection rather than developing a response specific to the
current DENV serotype causing the infection, further increasing the viral load due to
decreased viral clearance. There is also an increased production of cytokines by these T-
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cells and other uninfected bystander cells along with an increase in the apoptosis of
bystander cells, which can lead to heptatic injury. Additionally, there are autoimmune
factors involved in the pathogenesis of DENV. Antibodies to NS1 have been reported to
be cross-reactive with human platelets and endothelial cells. Antibodies against the E
protein are also cross-reactive with human plasminogen [305]. The interaction of these
cross-reactive antibodies with their targets within the host can further augment the
symptoms of DHF/DSS [304,306].
Overall in DHF/DSS there is an increase in the number of virally infected cells
due to both ADE and OAS, as well as an increased production of cytokines, some of
which are proinflammatory. These proinflammatory cytokines, especially TNF-α [307309], IL-6 [250,308], IL-8 [250] and IL-12 [250], interact with endothelial cells creating
leaky junctions, increasing the vascular permeability, and deficiencies in coagulation,
leading to the associated symptoms of DHF/DSS [250,309-311].
The pivotal role that antibodies play in either clearing or enhancing DENV
infections makes identifying neutralizing epitopes of the virus a key area of research.
Just six days after the bite from a DENV-infected mosquito, the body can begin to
develop a humoral immune response against the virus [266,296,312-315]. Most
protective antibodies, typical of this humoral immune response, are directed at the three
domains (DI, DII, and DIII) of the structural E protein [316-319]. The central domain,
DI, contains nonneturalizing epitopes and is thought to be involved in the low-pHtriggered conformation changes [320]. Neutralizing epitopes are found within the highly
conserved fusion loop in DII, which interacts with the host cell membrane during fusion
[320-323], and the lateral ride or fusion loop in DIII [247,271,319,324-326]. It has been
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found that for other flaviviruses, protective antibodies also recognize some of the NS
proteins (NS3 and NS5), and the prM protein [316,318,327]. However, the antibody
response against the NS proteins is weak, especially in primary DENV infections
[318,328].
Research completed with a common experimental strain of DENV-2 has
identified three major epitopes that are recognized by mammalian neutralizing antibodies:
the lateral ridge in DIII, the fusion loop in DII, and the less common A strand in DII of
the E protein [247,329]. Despite the protective potential of passive antibody treatments
for DENV infection, their use is hindered by the threat of ADE. It has previously been
shown that genetically modified mammalian IgG antibodies that bind DENV-2, but lack
the ability to bind FcγRs, work as prophylactic and therapeutic treatments against DENV2 infections without interference from ADE [270]. The difference in the Fc portion of
avian antibodies compared to mammalian antibodies makes avian monoclonal antibodies
a possible treatment for DENV infections. Avian antibodies have the potential to avoid
ADE and allow successful passive antibody treatment of DENV infections.
Goose Monoclonal IgY Antibodies as a Treatment Against DENV-2 Infections
The aim of this project was to develop a goose monoclonal IgY antibody that
could be used to as a treatment against DENV-2 infections. Avian monoclonal IgY
antibodies are a logical treatment option for DENV-2 infections because of their potential
to overcome the shortcomings of current therapeutic antibodies, including the HAMA
response and other adverse reactions because of the structural difference in the Fc portion
of mammalian IgG and avian IgY antibodies [44,46]. This is a favorable treatment
option over polyclonal antibodies because of the homogenous and consistent response
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that is generated. Once the hybridomas are developed, the monoclonal IgY antibodies
become a renewable resource. Using monoclonal IgY antibodies would also provide the
protection while preventing ADE and other complications caused by DENV-antibody
complex uptake.
In this study we show for the first time attempts to use traditional hybridoma
techniques to develop a goose monoclonal IgY antibody.

Materials and Methods
Geese
Geese were vaccinated against Pasteurella multocida types 1, 4, and 3x4 (the
causative agent of fowl cholera) at 12-18 weeks of age, and again four to six weeks later
using the AviPro 108 FC4 vaccine (Lohmann Animal Health, Winslow, Maine, USA).
Blood was collected from the vaccinated geese and used as a source of immune B-cells.
Geese were immunized subcutaneously with DENV-2 antigen (Microbix, Mississauga,
ON, Canada) derived from the parental DENV-2 strain PLO46 Taiwanese isolate [330].
Vaccinations took place on day zero with a 1:1 mixture of DENV-2 antigen with
complete Freund’s adjuvant. A booster vaccination was administered two and four
weeks later with a 1:1 mixture of the DENV-2 antigen with incomplete Freund’s
adjuvant. Six weeks later, blood was collected from the immunized geese. Geese were
housed in either an isolation unit (ISO) or specific pathogen free unit (SPF) for the
duration of the experiment.
Hybridoma Techniques
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Blood from vaccinated geese was separated using a ficoll-paque gradient. The
lymphocyte layer was isolated from the gradient and used as a source of immune B-cells.
Cells were then washed, and viability was determined in a hemocytometer using 0.2%
trypan blue. The goose immune B-cells were mixed with the Sp2/0-Ag14 mouse
myeloma cell line under fusion conditions with 50% polyethylene glycol (Polysciences,
Inc., Warringto, PA, USA).
To select for B-cell fusions, B-cells were cultured at 2.5x106 cells/mL in 96-well
plates in complete DMEM-20/HEPES/Pyruvate/HAT media (advanced DMEM),
supplemented with 2mM L-glutamine, 50μM 2-ME (Sigma, MO, USA), 100 U/mL
penicillin 100μg/mL, streptomycin sulfate, 20% fetal bovine serum (FBS) (Gibco BRL,
Grand Island, NY, USA), 10mM HEPES 1mM sodium pyruvate (Cellgro, Mediatech
Inc., VA, USA), and 10x HAT (Cellgro, Meditech Inc, Va, USA) at 37º C in 5%
humidified CO2 for two weeks. Before switching to DMEM/HEPES/Pyruvate/HT
containing media (advanced DMEM, supplemented with 2mM L-glutamine, 50μM 2-ME
(Sigma, MO, USA), 100U/mL penicillin 100μg/mL, streptomycin sulfate, 20% fetal
bovine serum (FBS) (Gibco BRL, Grand Island, NY, USA), 10mM HEPES 1mM sodium
pyruvate (Cellgro, Mediatech Inc., VA, USA, and 1x HT (Gibco, Grand Island, NY,
USA)), and then on day 15 and for the remainder of the experiment, cells were cultured
in DMEM/HEPES/Pyruvate media (advanced DMEM, supplemented with 2mM Lglutamine, 50μM 2-ME (Sigma, MO, USA), 100U/mL penicillin 100μg/mL,
streptomycin sulfate, 20% fetal bovine serum (FBS) (Gibco BRL, Grand Island, NY,
USA), 10mM HEPES 1mM sodium pyruvate (Cellgro, Mediatech Inc., VA, USA).
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After approximately three weeks, culture supernatants were screened for fowl
cholera- or DENV-2- specific goose antibodies. Hybridomas were ready to screen when:
1) there was 10-25% confluence in wells with cell growth, and 2) when the wells with
dense growth turned yellow within two days after feeding due to waste production.
Hybridoma Screening
Culture supernatants from wells containing potential hybridomas were screened
for either fowl cholera- or DENV-2- specific goose antibodies using an ELISA. Briefly,
one hundred microliters of DENV-2 antigen (Microbix, Mississauga, ON, Canada), or
fowl cholera vaccine was used as a capture antigen to coat Costar EIA/RIA96-well plates
(Corning, New York, NY, USA) and then incubated overnight at 4ºC. Plates were
washed five times with PBS/0.5% Tween-20 (PBST), and then blocked by adding 200μL
1% BSA in 1xPBS to each well after incubation for two hours at room temperature (RT).
Plates were washed five times with PBST before samples were added. Culture
supernatants samples were diluted 1:3. Serum from fowl cholera or DENV-2 immunized
geese was used as a positive control, diluted 1:50. One hundred microliters of samples
and controls were loaded into wells in triplicate. Samples were incubated overnight at
4ºC and washed five times with PBST. DENV-2 specific IgY was detected by incubation
with either an HRP-conjugated donkey anti-chicken IgY (Gallus Immunotech, Fergus,
ON, Canada) or AP-conjugated rabbit anti-chicken IgY (Sigma, MO, USA), for one hour
at 37ºC. The plates were washed five times with PBST and the reaction was visualized
with TMB substrate (Thermo Scientific, Rockford, IL, USA) or pNPP substrate (Thermo
Scientific, Rockford, IL, USA). The colorimetric change of each well was determined at
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an optical density of 450nm or 405nm on a Thermomax Microplate Reader (Molecular
Devices, Sunnyvale, CA, USA).
Cloning by Limiting Dilution
Candidate hybridomas were prepared at a concentration of 50 viable cells/well
and five viable cells/well in 10mL of cloning and expansion medium,
DMEM/HEPES/Pyruvate media supplemented with cloning media (advanced DMEM),
supplemented with 2mM L-glutamine, 50μM 2-ME (Sigma, MO, USA), 100 U/mL
penicillin 100μg/mL, streptomycin sulfate, 20% fetal bovine serum (FBS) (Gibco BRL,
Grand Island, NY, USA), 10mM HEPES 1mM sodium pyruvate (Cellgro, Mediatech
Inc., VA, USA), 5% BriClone (QED Bioscience Inc. San Diego, CA, USA). 96-well
plates were then seeded with the cell suspensions at 200μL per well and cells were
cultured at 37º C in 5% humidified CO2. Wells containing hybridoma clones were
screened for production of fowl cholera- or DENV-2- specific IgY antibodies using the
same ELISA screening method.

Results
Modification of Mammalian Hybridoma Techniques using Fowl Cholera
Preliminary work was done to first demonstrate the modification of mammalian
techniques to the avian system using geese vaccinated against fowl cholera caused by the
bacteria Pasturella multocida (P. multocida). Fowl cholera can infect both wild and
domestic birds causing either an acute or chronic infection, resulting in high morbidity
and mortality that spreads easily from bird-to-to bird within flocks. Asymptomatic and
chronic carriers play a key role in disease transmission. Disease prevention is important

60

especially for commercial farmers to prevent fowl cholera from wiping out their flocks.
Blood was used as an alternative source of immune B-cells. Blood was collected from
geese vaccinated against fowl cholera. The lymphocyte layer was isolated from goose
blood separated using a ficoll-paque gradient. The purified goose B-cells were fused
with mouse myeloma cells (Sp2/0-Ag14) at a 1:1 ratio in the presence of 50% PEG and
grown in HAT containing media to select for the growth of only B-cell-myeloma cell
fusions. After three weeks of growth, culture supernatants were screened for the
production of anti-cholera IgY antibodies using an ELISA.
Supernatant from sixty potential hydridoma containing tissue culture plate wells
was screened. Anti-fowl cholera IgY antibody levels in culture supernatant were
compared to the anti-cholera IgY antibody levels found in serum from fowl cholera
vaccinated geese; antibodies found in the serum were used as a positive control. Results
for 41 a hybdridoma that did not produce any fowl cholera- specific IgY antibodies are
inducled for comparison. Of the sixty wells screened, six contained high responding
hydridomas, 6, 16, 18, 21, 22, and 24 (Fig 1). These hybridomas produced higher
amounts of anti-cholera IgY antibodies than the three low responder hybdriomas 52, 59,
and 60 (Fig 1). These results demonstrated that it is possible to make goose B-cell
hybdridoma using mammalian techniques and supports the feasibility of the development
of a goose monoclonal IgY antibody. Focus was then shifted to making goose
monoclonal IgY antibodies against the relevant human pathogen DENV-2.
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Figure 1. Presence of fowl cholera specific IgY antibodies as determined by ELISA.
Culture supernatants from potential hybridoma containing tissue culture wells were
collected approximately three weeks after fusion and analyzed for the presence of fowl
cholera specific IgY antibodies by ELISA. Serum from vaccinated geese was used for
comparison. Readings were taken at an optical density (OD) of 450nm. Each sample
was run in triplicate and the bars represent standard error.
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Development of DENV-2 Specific Goose Monoclonal IgY Antibodies
This study focused on the development of a goose monoclonal IgY antibody using
the modified mammalian hybridoma technique developed using fowl cholera. Female
geese housed in either an ISO or SPF unit were vaccinated with a DENV-2 antigen in
adjuvant on experiment day zero, and then booster vaccinated two and four weeks later.
Eggs and blood were collected from the vaccinated geese weekly starting two weeks into
the experiment. The lymphocyte layer containing immune B-cells was isolated from
blood collected from DENV-2 antigen vaccinated geese using a ficoll-paque gradient.
The immune goose B-cells were fused with the Sp2/0-Ag14 mouse myeloma cell line at a
1:1 ratio to form hybridomas. This process was repeated several times as new blood
samples were received. After approximately three weeks of incubation in various types
of media, culture supernatants from wells containing potential hybridomas were screened
using an ELISA.
Twenty-nine potential hybridoma containing wells were screened for the presence
of DENV-2 specific IgY antibodies. Serum from the immunized geese showed
detectable amounts of DENV-2 specific IgY antibodies and was used as a positive
control in the ELISAs (Fig 2). Of the 29 wells screened, six were producing high levels
of DENV-2 specific IgY antibodies: those in wells C1, E6, E8, F2, H3, and D6. Results
for E1, a hybridoma that did not produce any DENV-2 specific IgY antibodies, are
included for comparison. The DENV-2 specific IgY antibody levels produced from the
hybdridoma present in well C1 were higher than that of the positive control goose sera
(Fig 2). The hybdriomas present in wells C1, E6, E8, F2, H3, and D6 were subcloned by
limiting dilution in cloning/expansion medium containing a subcloning media
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supplement. After limiting dilution, culture supernatants were again screened for the
presence of DENV-2 specific IgY antibodies. There were no DENV-2 specific IgY
antibodies detected in any of the culture supernatants from wells containing the
subcloned hybdriomas or the parent hybdriomas compared to controls (data not shown).
This suggests the fusion between the goose B-cells and mouse myeloma cells cannot be
maintained over a long period of time.
IgY antibodies were also isolated from the yolks of eggs collected from
vaccinated geese and an ELISA was completed to confirm the presence of DENV-2
specific IgY antibodies and to determine the titers of the antibodies present in the eggs.
Because IgY is transferred from the serum of the goose to the egg yolk to protect the
developing embryo, egg yolk IgY antibody titers are also indicative of serum titers. The
average titer of IgY antibody from the eggs of geese housed specifically in the SPF
facility was 1:732,459, with the highest being 1:6,400,000 (Fig 3). For the eggs of geese
from the ISO unit, the average titers was 1:877,465, with the highest titer being 1:3,
200,000 (Fig 3). There results indicate that an active immune response was formed
against the DENV-2 antigen by the geese, and that DENV-2 specific immune B-cells are
present in the blood of vaccinated geese.
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Figure 2. DENV-2 specific IgY antibodies were initially present in culture supernatants
from candidate hybridomas. Culture supernatant samples were collected from candidate
hybridoma containing wells approximately three weeks after fusion with myeloma cells.
The presence of antigen specific DENV-2 antibodies was detected using an ELISA read
at an OD of 450nm. Serum from vaccinated geese was used as a positive control for
comparison. Each sample was run in triplicate, and bars represent standard deviation.
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Figure 3. DENV-2 specific IgY antibody is present in the yolks of eggs collected from
immunized geese. Eggs were collected from vaccinated geese housed in both the ISO unit
(closed circle) (n=71) and SPF unit (open circle) (n=61), respectively. A sample was
collected from each egg after processing for IgY antibody isolation. DENV-2 specific
IgY antibody titers present in the eggs were determined using an ELISA. Arrows
indicate booster immunizations. Data presented is a representative mean and bars
indicate standard error.
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Discussion
We show in this study, for the first time, that is possible to develop short-lasting
hybdridoma fusions between goose B-cells and mouse myeloma Sp2/0-Ag14 cells
capable of producing antigen- specific monoclonal avian IgY antibodies. Previously,
monoclonal IgY antibodies have been developed using murine/avian chimeric constructs
and phage display techniques [331,332]. However. chimeric antibodies utilizing the
constant region of an avian IgY antibody, and the variable region of mammalian IgG, are
still limited to the antigens they can recognize by the mammalian variable region, which
is responsible for binding the antigen [59]. These antibodies would not be useful against
targets that are highly conserved in the mammalian system, which is why the ability to
make completely avian monoclonal antibodies is advantageous. In the present study, it
has been shown that, at least the initial stages of hybridoma, development is possible
using traditional mammalian hybdridoma techniques, fusing goose B-cells and mouse
myeloma cells.
Vaccination against fowl cholera and immunization with DENV-2 antigens
induced strong humoral responses in the geese, as shown by the amount of antigen
specific IgY antibody detected in the serum of immunized geese (Fig 1 and Fig 2). This
coincides with research that emphasizes the role of antibodies in the immune response to
DENV-2 infections [296]. Dengue specific IgG antibody is present in the serum of
DENV-2 infected patients after just a week of illness [227,296]. Similarly, DENV-2
antigen specific titers were maintained within eggs at least six weeks into the experiment,
and peaked with titers well into the millions (Fig 3). The high antibody titers in the eggs
and the positive response by the serum from DENV-2 geese are both evidence for the

67

development of a humoral response by these geese against the DENV-2 antigen. The
development of a humoral response also means antigen- specific antibody producing Bcells are present in the blood of the vaccinated geese. Therefore, a lack of immune Bcells was not the main contributing factor to the problems with hybridoma development.
These results also support the general assumption that birds develop a robust immune
responses against a diverse array of antigens.
The fowl cholera vaccine used in these experiments, was an inactivated vaccine
formulation containing inactivated P. multocida in an oil-based emulsion. We report here
that vaccination induced high serum anti-fowl cholera IgY antibody production. This is
in agreement with studies completed in turkeys infected with an avirulent fowl cholera
vaccine, in which systemic antibody titers were induced [333,334]. The efficacy of such
vaccine formulations have also been studied in chickens and have been shown to be
effective in protection against bacteria challenge [335,336]. These results, along with
those of others, support the presence of fowl cholera specific immune B-cells in the blood
of vaccinated geese and confirms the successful development of antibody producing
hybdriomas between goose immune B-cells and mouse myeloma cells.
There was a reasonable amount of variability in the amount of fowl choleraspecific goose monoclonal IgY antibodies detected in the cultured supernatants from the
various hybdriomas. This varability in results could have been due to an uneven coating
of the ELISA plates. ELISA plates used to detect the fowl cholera specific IgY
antibodies were coated with a vaccine in an oil-based emulsion, the extra material present
in this preparation could have caused an uneven coating of the plate with the target
antigen and led to variability in results.
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Chicken monoclonal antibodies have been produced using hydbridoma
technology: through fusion of immune B-cells with either a chicken B-cell line, or
chicken non-secreting mouse myeloma cell line, both of which are not commercially
available [337-343]. These chicken monoclonal antibodies were developed against
various antigens, including prions and protozoa. Antigen specific IgY antibody
production by chickens was induced using a similar method as in these currently
described experiments [339,341,342]. Chickens were immunized with a given antigen
and then fusion experiments were completed with the chicken cell lines. One difference
between their protocol and that of this study was the use of immune spleen cells from the
immunized chickens as a source of antigen specific B-cells for fusion with the chicken
cell lines. In this study immune B-cells from the blood were fused with the mouse
myeloma cells. Monoclonal IgY antibodies made by fusing immune spleen cells with
chicken non-secreting myeloma cells lines were reported to continue to produce high
levels of antigen- specific IgY antibody for over six months even after subcloning [340].
It is possible that the chicken myeloma cells would work as a cell fusion partner for the
goose B-cells and lead to successful hybdriomas, but the difference in antibodies
produced by anseriformes birds (geese) and galiformes birds (chickens), mainly the lack
of IgY(ΔFc) production by chickens when compared to geese, could impact fusion
viability. Using an alternative source of goose immune B-cells could have been one way
to increase the fusion strength between the goose B-cells and mouse myeloma cells.
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CHAPTER III
CHARACTERIZATION OF ANDES VIRUS SPECIFIC IGY ANTIBODIES
FROM DNA VACCINATED GEESE FUR USE AS AN ANTI-VIRAL
TREATMENT
Introduction
History of Andes Virus in Humans
The Andes virus (ANDV) is a New World Hantavirus from the genus Hantavirus
within the Bunyavirdae family of viruses. The 21 hantaviruses that cause disease in
humans are distributed worldwide, and can be differentiated based on phylogenetic
origins into Old World and New World hantaviruses. Old World hantaviruses can be
found in Asia and Europe, and New world hantaviruses can be found in North, Central
and South America. Along with differences in location, New and Old World
hantaviruses also differ in the type of syndrome they cause. Old World hantaviruses
cause a hemorrhagic fever with renal syndrome (HFRS) while New World Hantaviruses
cause hantavirus pulmonary syndrome (HPS).
In the past century there have been two major disease outbreaks that led to the
discovery of both the Old and New World hantaviruses. The first outbreak occurred
during the Korean War in the early 1950s, during which over 3,000 military troops fell ill
with a hemorrhagic fever, later determined to be HFRS [344,345]. In 1978, the Hantaan
virus, an Old World hantavirus, was identified as the causative agent of the troops cases
of HFRS [346]. The second outbreak occurred in the Four Corners region of the United
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States in 1993. Adults in this region were afflicted with a severe respiratory illness
caused by a virus, later identified as HPS caused by the Sin Nombre virus (SNV), a New
World hantavirus [347]. In 1995, a hantavirus similar to SNV was identified in South
America, the ANDV. ANDV was first reported and identified as the causative agent of a
HPS outbreak in Argentina [348-350]. Since then additional outbreaks of HPS caused by
ANDV have occurred throughout South and Central American, including Brazil, Chile,
and Uruguay [351,352]. ANDV continues to be the only hantavirus known to cause HPS
in Chile.
Within the Bunyaviridae family hantaviruses are unique in that they are mainly
transmitted to humans by the inhalation of virus particles that become aerosolized from
the excrement or bodily fluids (urine, feces, or saliva) of chronically infected rodents
[353]. Infection of the reservoir rodents is primarily subclinical. In nature, transmission
of the virus between reservoir and non-reservoir rodents is thought to occur primarily
through aggressive behavior and exposure to saliva and excreta [354,355]. It has also
been shown that rodents can transmit virus through infected excrement within rodent
nests [356-358]. Hantaviruses follow the single virus/single host rule of natural
reservoirs, meaning each hantavirus has a specific rodent species as a natural host
[345,359,360]. As a result, the geographical distribution of different hantavirus strains is
determined by the distribution of their rodent reservoir. The primary natural reservoir for
the ANDV in Chile is the Oligoryzomys longicaudatus, the long- tailed pygmy rat [361].
Along with normal rodent transmission, ANDV is the only hantavirus that is
known to be transmitted person-to-person [352,362,363]. Person-to-person transmission
occurs primarily within families or between sexual partners due to the likelihood of close
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contact with the infected person [364]. This type of transmission is more likely to occur
during the prodromic phase of disease. This is an early stage of disease that can range
from 12 to 27 days [363,365]. Other examples of transmission are by bites from rodents
and blood transfusions [351,366]. In Chile, more than half of the HPS cases are
associated with outdoor occupations such as forestry or agriculture [367,368]. Seasonal
HPS cases in Chile during November to April are typically a result of outdoor
recreational activities (20-35% of reported cases) during which time individuals are more
likely to come in contact with infected rodents [367,368]. HPS outbreaks can be
unpredictable, localized, and sporadic due to fluctuations in the rodent reservoirs and
changes in the prevalence of the hantaviruses in the reservoirs. In the Americas, the
emergence of hantaviruses has been linked to precipitation [369,370]. Studies suggest
that precipitation can indirectly increase reservoir species populations and therefore
hantavirus prevalence [369,371,372].
ANDV Structure and Life Cycle
ANDV is an enveloped virus with a negative sense trisegmented single-stranded
RNA genome. The three genome segments S, M, and L encode for three different
proteins: the nucleocapsid (N) protein, two glycoproteins Gn and Gc, and an RNAdependent RNA-polymerase (RdRp), respectively [373]. Within the virion the three
genome segments are individually encapsidated by N proteins to form ribonucloproteins
(RNPs) [373-375]. Hantaviruses are spherical in shape with a grid-like pattern on their
outer surface due to G1 and G2 heterodimers projecting from the lipid bilyaer surface of
the virus.
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ANDV and other hantaviruses primarily target vascular endothelial cells of the
lung and macrophages for replication. Entry is most often facilitated by attachment of
the virus to β3 integrins on the surface of the cell, followed by endocytosis into the cell
[376-378]. These may not be the only receptors for the virus because cells without β3
integrin also allow hantavirus infection [379,380]. After internalization the virions are
trafficked to either an early or late endosome. The low pH of the endosome triggers a
conformational change in the G2 glycoprotein allowing fusion of the viral and cellular
membranes [381-383]. The viral genome, in the form of RNPs, is then released into the
cytoplasm and transported to the site of viral replication within the cell [384,385]. This
allows the viral genome to be used as a template in two different processes: transcription
and replication. Both transcription and replication are facilitated by the viral RdRp [386].
Initially transcription is started by the viral RdRp to give rise to the S, M, and, L mRNAs.
The S and L mRNA transcripts are then translated on free ribosomes, and the M segment
transcript is translated on membrane-bound ribosomes, which is cotranslated on the rough
endoplasmic reticulumn (RER) [351]. The glycoprotein precursor that results from
translation of the M segment transcript is proetolytically processed into the G1 and G2
glycoproteins during import into the ER [386,387]. The resulting G1 and G2
glycoproteins are also glycosylated in the ER and then transported to the Golgi complex
[387,388]. After the initial burst of transcription, the viral RdRp switches to replication
of the viral S, M, and L genomic RNAs [351]. The first step in replication is transcribing
the vRNA into complementary RNA (cRNA), which is then used as a template [383].
Replication can then proceed using the cRNA de novo without the need for primers
[386]. After the viral genome has been replicated it is then encaspidated by the N protein
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to form RNPs [389]. When enough viral components have been made assembly can take
place. For New World hantaviruses it is most likely that assembly takes place at the
Golgi complex where the G1 and G2 proteins accumulate, but evidence suggests that this
step might also take place at the plasma membrane [390-392]. During assembly the
RNPs for each genome segment along with L proteins come together and the virion buds
inside of the Golgi, through the host membrane with G1 and G2 embedded in it, and is
subsequently release into the mileu from the Golgi, probably by exocytosis [393].
Alternatively the virion could bud directly through the plasma membrane, with G1 and G2
embedded in it, entering the cellular mileu [392]. Infected cells are not lysed during
infection with hantaviruses [394,395].
HPS caused by ANDV
Following infection of target cells, ANDV leads to HPS by indirect effects of the
virus on endothelial cell barrier function. Activation of the innate and adaptive immune
responses leads to the production of proinflammatory cytokines and disease specific
immunopathology. The most damage caused by ANDV is focused on the lungs and
typically presents as a quickly developing diffuse non-cardiogenic pulmonary edema
[396]. The average incubation period for ANDV is 18-19 days with a possible range of
11-32 days [397,398]. Current hantavirus diagnostic tests are capture ELISAs that detect
the IgG/IgM response to the viral N protein [399,400]. For HPS infections the initial
prodromal period lasts two to five days with symptoms of fever, headache, back pain,
myalgia, and gastrointestinal symptoms [401]. Thrombocytopenia is one of the earliest
laboratory findings of HPS, seen in more than 80% of patients, and can be detected as
early as the prodromal phase of illness [402,403]. As the condition continues to worsen,
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patients will begin to experience HPS specific respiratory symptoms such as cough,
shortness of breath, tachycardia, and hypotension [402,404]. More severe
cardiopulmonary symptoms arise from an increase in pulmonary edema and low cardiac
output [405]. This can quickly lead to respiratory failure, often requiring treatment with
supplemental oxygen, intubation, or intubation with mechanical ventilation [406]. The
final stage of illness is the development of non-cardiogenic shock from the increased
capillary permeability caused by inflammatory damage to the pulmonary vascular
endothelium [404]. After the cardiopulmonary stage of illness, thrombocytopenia
continues to be a detectable laboratory finding along with circulating immunoblasts, and
elevated hematocrit values [407,408]. Gross pathological findings show that the lungs of
patients with HPS are dense, rubbery, and heavy, usually weighing twice as much as the
average lung [399]. Almost all deaths due to HPS occur 24-48 hours after the onset of
cardiopulmonary symptoms and are a result of shock [351]. The mortality rate for HPS is
approximately 50%, but it can vary depending on the specific hantavirus causing the
infection [394,409]. If patients survive the acute phase of HPS, the convalescent period
can be long; often patients experience weakness and fatigue with abnormal lung capacity.
It may take months to years to fully return to normal [397,410].
Despite the relatively high mortality rate there continues to be no virus- specific
treatment or vaccine for HPS caused by ANDV. This makes treatment for HPS only
supportive in nature. Patients often receive intravenous fluids and supplemental oxygen.
Another setback to the development of a HPS treatment has been the lack of a quality
rodent model of infection. It was not until recently that a quality lethal rodent model of
infection was developed. ANDV causes a lethal disease in adult Syrian hamsters that
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closely resembles disease in humans. The Syrian hamster model has been a useful tool to
study potential treatments and gain a better understanding of both the disease
pathogenesis and the immune response to the virus [411].
Immune Response to ANDV
The immune response is a necessary evil during a hantavirus infection: it is
necessary to clear the infection, and develop immunological memory to prevent future
infections, but it can also exacerbate the symptoms of infection. Initially when a
hantavirus infects a host cell it is recognized by various PRRs that will lead to the release
of proinflammatory and anti-viral cytokines including type 1 IFNs and IFN-γ [412].
These two groups of IFNs will work together as the first line of defense to restrict viral
replication and spread of the virus.
Hantaviruses have developed several ways to evade the host IFN response
including changing the look viral transcripts. The viral G1 and G2 glycoproteins are able
to down regulate the IFN pathways by inhibiting IRF-3 phosphorylation, dimerization,
and nuclear transport, along with impairing the function of IKKe and TBK-1 kinases
[413,414].
Infected macrophages are activated to produce cytokines such as TNF-α, IL-6,
and IL-1 [351]. Those same cytokines along with IL-2 and IFN-γ can be detected in the
lung tissues of patients with HPS during early stages of infection. These cytokines are
most likely being produced by infected macrophages and monocytes within the tissue
[415]. In vitro, hantavirus infection of endothelium results in the induction of MCP-1,
RANTES, and IP-10, all of which can recruit immune cell infiltrates to the lungs and
other organs [395,416,417]. Furthermore, the excess of proinflammatory cytokine
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production by immune cells is probably critical for HPS pathogenesis. TNF-α is known
to affect vascular permeability and results from clinical patients suggests that the IL-6
plays a role in inhibiting cardiac function and inducing hypotension in HPS [351].
A robust CD4+ and CD8+ T-cell response is also activated against hantaviruses.
CD8+ T-cells play a major role in the induction of HPS, whereas CD4+ T-cells play a
more protective role by activating B-cells to produce protective neutralizing antibodies.
Patients with severe HPS have higher amounts of virus- specific CD8+ T-cells present in
their blood compared to patients with moderate disease, and those infected with other
viruses [418]. T-cells obtained from patient’s blood primarily recognize epitopes within
the N, G1, and G2 proteins [418-420], with the most immunodominant epitopes being part
of the G1 protein [421]. Other studies indicate that G1- specific effector memory T-cells
may contribute to protective immunity in ANDV infected patients [421].
Activation of the humoral immune response and production of neutralizing
antibodies are essential to suppress hantavirus dissemination and to avoid fatal disease.
Both IgM and IgG hantavirus- specific antibodies can be detected at or shortly after the
onset of the prodromal period. Initially, antibodies are derived against the N protein, and
then later after the development of clinical symptoms almost all patients will develop
IgM and IgG antibodies specific for the G1 protein [422]. It was shown that HPS patients
with mild HPS had higher neutralizing antibodies titers to SNV or ANDV than those that
with severe HPS [350,423]. Also, higher hantavirus specific IgG levels early in disease
have been associated with survival [424]. After convalescence from hantaviral infection,
humans are considered to be protected for life from reinfection [405].
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The importance of the humoral response in protection against HPS infections
caused by the ANDV is further supported by the ability to passively transfer protection
through the transfer of neutralizing antibodies. Research has shown that plasma from
HPS survivors is protective in the ANDV hamster model of infection [425]. Vaccine
induced neutralizing antibodies collected from the serum of rhesus macaques or rabbits
vaccinated with a DNA vaccine also protected against lethal disease development in the
ANDV hamster model when given before or up to five days post-challenge [425,426].
As a means to prevent the risks of reactionicity associated with the use of mammalian
antibodies, duck IgY anti-ANDV antibodies were generated from the egg yolks of ducks
vaccinated with a DNA. The anti-ANDV IgY and IgY(ΔFc) antibodies were able to be
used as a treatment in the ANDV Syrian hamster model of infection when administered
after challenge [427]. These results provide direct evidence that goose- derived antiANDV IgY antibodies can be used a passive antibody treatment against HPS caused by
the ANDV.
Despite the encouraging studies that support the use of a passive treatment against
HPS, current options are not fulfilling the need. Human convalescent serum is in short
supply, has risks of reactogenicity in humans, and is often contaminated with other
infectious pathogens. There are currently no neutralizing monoclonal antibodies
available. To fill this gap. this study demonstrates post-exposure treatment potential of
goose-derived anti-ANDV antibodies both in vitro and in vivo. In addition, the study
identified epitopes within the ANDV glycoproteins recognized by IgY/IgY(ΔFc)
antibodies purified from egg yolks of DNA vaccinated geese. It is also shown that
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neutralizing titers were maintained during the time period between initial and booster
vaccination, and the neutralizing titers were increased after booster vaccination.

Materials and Methods
Virus and Cells
ANDV strain Chile-9717869 was propagated in Vero E6 cells (Vero c1008
ATCC CRL 1586, Manassas, VA). Cells were maintained in Eagle’s minimal essential
medium with Earle’s salts (EMEM) (EMEM, supplemented with 10% FBS, 10mM
HEPES (pH 7.4), 200U/mL penicillin, 200ug/mL streptomycin, 1x nonessential amino
acids, 1.5μg/mL amphotericin B, and 50ug/mL gentamicin sulfate), at 37ºC humdified in
a 5% CO2 incubator.
Vaccination of Geese
Naïve geese were vaccinated with the ANDV DNA vaccine pWRG/AND-M(opt)
(1mg) at two week intervals starting at day zero for ten weeks. Injections were given
intramuscularly (i.m.) using a needle free device (NFD). One year later the same geese
were booster vaccinated with either the same pWRG/AND-M(opt) or an optimized
version of the same vaccine pWRG/AND-M(opt2). Six 1mg injections were
administered over a ten week time period. Goose eggs were collected after initial
vaccination and booster vaccination at time point indicated in figure 4. Sera was also
collected from the vaccinated geese at five different time points both after the initial and
booster vaccination series as indicated in figure 4.
Epitope Determination
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Linear IgY epitopes were identified using JPT PepStar microarrays (JPT, Berlin,
Germany). The entire glycoprotein precursor sequence of the ANDV strain Chile9717869 was synthesized into 13 amino acid overlapping peptides. The resulting 376,
13-mer peptides were covalently attached to a microarray slide, with a 10 amino acid
overlap between adjacent sample peptides. Peptides were analyzed for their reactivity
with IgY antibodies isolated from goose eggs, following protocols recommended by JPT.
Briefly, slides were incubated with the primary antibody diluted to 30μg/mL at 4°C
overnight in a moist environment. The slide was washed and incubated with a
fluorescently labeled secondary antibody, goat anti-chicken IgY conjugated to Cy5
(1μg/mL) (Abcam, Cambridge, England) for 1 hour at 30°C. After washing and drying
the slide, bound antibodies were detected using a microarray reader (Genepix 4000).
Fluorescence was measured at a 10μm pixel size and mean values with the background
corrected were calculated and used for analysis. The reactivity was classified based on a
spectrum ranging from no activity in black, mild reactivity in gray, to strong reactivity in
red.
PsVNA
Pseudovirion assays (PsVNA) utilized a replication deficient vesicular somatic
virus (VSV) coated with the ANDV glycoproteins and the VSV surface glycoprotein
gene replaced with a Renilla luciferase reporter gene to be used for quantification. The
assay was completed as follows. Vero cells were seeded at 1x104 cells/well in a 96-well
plate and grown overnight. Pseudovirions were pre-incubated with antibody treatments
at 37ºC for 30 minutes before being added to cells. The pseudovirion/antibody mixtures
were incubated in wells containing cells for one hour at 37ºC, after one hour the
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pseudovirion/antibody mixtures were removed and replaced with 200μL of fresh DMEM
supplemented with 10% FBS. Luciferace levels were measured 24 hours after infection
using a luciferase assay system (Promega, Madison, WI).
ANDV challenge of hamsters and passive treatment
Adult female Syrian hamsters (Mesocricetus auratus) were injected i.m. in the
caudal thigh, using a 25-gauge 5/8-in. needle, with ANDV diluted in 0.2mL of sterile
PBS (pH 7.4). The challenge dose for ANDV was 2,000 PFU, which is 250 LD50 doses.
Work involving ANDV infected hamsters was completed in a biosafety level 4
laboratory.
Five and eight days post-challenge hamsters were anesthetized by i.m injection with
approximately 0.1mL/100g of body weight of a ketamine-acepromazine-xylazine
mixture, and then subcutaneously (s.c.) injected with, one of the six following treatments:
(1) anti-ANDV rabbit sera, (2) anti-ANDV goose sera, (3) anti-ANDV purified IgY, (4)
normal goose sera, (5) normal purified IgY, or (6) no treatment. The effects of challenge
and subsequent antibody treatment on the survival outcome of the hamsters was assessed.

Results
Experimental Design
Previous work has demonstrated that anti-ANDV polyclonal IgY/IgY(ΔFc)
antibodies from the eggs of vaccinated ducks limited the infection in the ANDV/Syrian
hamster model when administered five to eight days after intranasal (i.n.) ANDV
challenge [427]. This provides evidence for the use of anti-ANDV IgY antibodies as a
post-exposure treatment for ANDV. To further investigate the treatment potential of IgY
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antibodies against ANDV infection and identify other sources for IgY, polyclonal IgY
and IgY(ΔFc) antibodies were isolated from goose egg yolks. Geese were vaccinated
with an ANDV DNA vaccine, pWRG/AND-M (Fig 4A), that contains the full-length M
genome segment of ANDV strain Chile- 9717869, at two-week intervals up until 8 weeks
and then at 12 weeks using a needle-free device. One year later the immune geese were
booster vaccinated with either pWRG/AND-M or pWRG/AND-M(opt) at week 53, 54,
56, 60, 61, and 62 (Fig 4B). Eggs were collected from the vaccinated geese after the
initial vaccination series and immediately after the long-range booster vaccination series.
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Figure 4. Experimental design. Geese were vaccinated i.m. with 1mg ANDV DNA
vaccine pWRG/AND-M at 2 week intervals for 10 weeks, using a needle free device.
One year later the same, geese were booster vaccinated again with 1mg ANDV DNA
pWRG/AND-M(opt) or pWRG/AND-M(opt2) vaccine on weeks 52, 54, 56, 60, 61, and
62. Sera was collected from the vaccinated geese during the times indicated by red
arrows. Eggs were collected, after the initial vaccination series and after the booster
vaccination as indicated by yellow ovals.
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IgY Antibodies Isolated from Eggs of ANDV Vaccinated Geese Recognize Unique
Epitopes On ANDV Glycoproteins G1 and G2
To determine the specificity of the IgY/IgY(ΔFc) antibodies purified from the egg
yolks of vaccinated geese, epitope mapping was completed using microarray slides. The
M genome segment is the primary viral component of the ANDV DNA vaccine; two
glycoproteins G1 and G2 are synthesized from the M segment and are present in dimers
on the outside surface of mature ANDV virions. Based on vaccine composition and virus
structure it was hypothesized that antibodies produced by vaccinated geese would bind to
epitopes present on the ANDV glycoproteins. To identify potential epitopes on ANDV
glycoproteins G1 and G2 recognized by anti-ANDV goose IgY and IgY(ΔFc) antibodies.
Microarray slides were covalently linked with 13-mer peptides with a 10 amino acid
overlap, for a total of 376 peptides, spanning the entire sequence of the glycoproteins
from ANDV strain CHIL 9717869 (GenBank accession number AF291703). Total
IgY/IgY(ΔFc) antibodies from the egg yolks of geese receiving the initial vaccination
series was separated into full length IgY antibody and the alternatively spliced IgY(ΔFc)
antibody fractions for testing with microarray slides; unseparated IgY/IgY(ΔFc)
combination was also tested. IgY/IgY(ΔFc), IgY(ΔFc), or IgY/IgY(ΔFc) antibodies
purified from the eggs of geese vaccinated at both initial and booster vaccination time
points were incubated with microarray slides. Reactivity was compared to negative
control features on the slide that did not contain any protein; the average of the negative
controls was taken and used for comparison.
Eleven IgY/IgY(ΔFc) antibody reactive epitopes were identified across
glycoproteins G1 and G2 (Fig. 3A and 3B). Seven of the epitopes were specific for the G1
glycoprotein, peptides starting with aa 121-130, 166-169, 205-211, 241-247, 511, 589,
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and 613-625 (Fig 5), and the remaining four epitopes were within the G2 glycoprotein,
reactive peptides started with aa 679-685, 727-745, 787-799, and 889-892 (Fig 6). When
comparing the epitopes recognized by IgY/IgY(ΔFc) antibodies to the separated IgY or
IgY(ΔFc) antibodies, some of the epitopes were recognized exclusively by IgY(ΔFc)
antibodies, (e.g., peptides aa 1024), while others were recognized by both even when
separated and incubated with the microarray slides independently. There were also some
regions that elicited a higher reactivity from IgY antibodies versus IgY(ΔFc) antibodies
(e.g., peptides starting with aa 121-130 and 166-169). There was no reactivity detected
with all negative control slide features (Fig 5 and Fig 6).
Because geese receiving the booster vaccination showed increased neutralizing
IgY antibody titers compared to the initial vaccination, we wanted to see if there was any
change to the epitopes recognized by IgY/IgY(ΔFc) antibodies from the booster
vaccinated geese. Figures 5 and 6 (column 4) show that IgY/IgY(ΔFc) antibodies from
the egg yolks of the booster vaccinated geese reacted with all of the same epitopes as the
IgY/IgY(ΔFc) antibodies from the initial vaccination. Reactivity of the booster
IgY/IgY(ΔFc) antibodies with these epitopes was either at the same reactivity level or
increased. Additionally there were nine new regions of reactivity with the booster
IgY/IgY(ΔFc) antibodies compared to all other IgY treatments, corresponding to peptides
starting with aa 31-40, 82-85, 259, 355, 475, 484-493, 640, 691-697, and 940-955 (Fig 5
and Fig 6). One region of high reactivity was extended from seven peptides being
recognized, start aa of 727-745, to 10 peptides 707-754. This could be due to an
additional epitope being recognized or an increase in the area of being recognized, after
booster vaccination.
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Sera from rabbits that were previously vaccinated with pWRG/AND-M were also
incubated with microarray slides to determine potential epitopes recognized by
mammalian antibodies generated after vaccination. In general, the rabbit sera IgG
antibodies recognized similar ANDV glycoprotein epitope regions as all IgY treatments.
But, for a majority of the epitopes that were recognized by both rabbit sera IgG
antibodies and goose egg IgY antibodies there was an obvious difference in reactivity.
The rabbit IgG antibodies were less reactive than the IgY antibodies. There was
increased binding by the rabbit IgG antibodies to only one region, peptides starting with
aa 313 and 358 in G1, when compared just to all IgY treatments (Fig 5). Areas of notably
decreased reactivity compared to all IgY treatments were found in both G1 and G2,
specifically the peptides starting with aa 511, 589, and 685-697 (Fig 5 and Fig 6). When
comparing the reactivity of rabbit IgG antibodies to IgY/IgY(ΔFc) antibodies from the
eggs of booster vaccinated geese, there was one obvious region of decreased reactivity in
G1 corresponding to the peptide starting with aa 34 (Fig 5). There were two unique
epitope recognized strongly by the rabbit IgG antibodies compared to IgY/IgY(ΔFc)
antibodies from the eggs of vaccinated geese comprised of peptides starting with aa 223229 in G1 along with peptide 760 in G2 (Fig 5 and Fig 6).
Of the reactive epitopes identified, those with the highest reactivity were in the
regions of peptides starting with aa 613-625 in G1 and peptides starting with aa 727-745
in G2 (Fig 5 and Fig 6). These two regions were recognized by all IgY treatments to the
highest reactivity level. These two regions were also recognized by the rabbit sera, but to
a lesser reactivity level than all of the isolated IgY treatments. Both of these highly
reactive regions are outside of the regions identified as reactive by convalesecent human
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sera from ANDV patients, and sera from naturally infected rodents [428]. Taken together
these results show that IgY isolated from eggs yolks of vaccinated geese was ANDV
specific and recognized unique epitopes compared to human and rodent serum.
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Figure 5. Identification of ANDV glycoprotein G1 epitopes. Amino acid sequence for
glycoproteins of ANDV strain Chile 9717869 used to make 13-mer peptides for
microarray slide. G1 microarray slides were incubated with IgY antibodies, IgY(ΔFc)
antibodies, or IgY/IgY(Fc) antibodies isolated from egg yolks of vaccinated geese either
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after the initial or booster vaccination series, or serum from vaccinated rabbits (first
column- amino acid peptide starts with, second column- IgY antibodies from egg yolks
after initial vaccination series, third column- IgY(ΔFc) antibodies from egg yolks after
initial vaccination series, fourth column- IgY/IgY(ΔFc) antibodies from egg yolks after
initial vaccination series, fifth column- IgY/IgY(ΔFc) antibodies from egg yolks after
booster vaccination, sixth column- sera from DNA vaccinated rabbit). Reactivity was
measured based on a spectrum ranging from no activity in black, mild reactivity in gray,
to strong reactivity in red (E-Empty features).
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Figure 6. Identification of ANDV glycoprotein G2 epitopes. Amino acid sequence for
glycoproteins of ANDV strain Chile 9717869 used to make 13-mer peptides for
microarray slide. G2 microarray slides were incubated with IgY antibodies, IgY(ΔFc)
antibodies, or IgY/IgY(Fc) antibodies isolated from egg yolks of vaccinated geese either
after the initial or booster vaccination series, or serum from vaccinated rabbits (first
column- amino acid peptide starts with, second column- IgYantibodies from egg yolks
after initial vaccination series, third column- IgY(ΔFc) antibodies from egg yolks after
initial vaccination series, fourth column- IgY/IgY(ΔFc) antibodies from egg yolks after
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initial vaccination series, fifth column- IgY/IgY(ΔFc) antibodies from egg yolks after
booster vaccination, sixth column- sera from DNA vaccinated rabbit). Reactivity was
measured based on a spectrum ranging from no activity in black, mild reactivity in gray,
to strong reactivity in red (E-Empty features).
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IgY/IgY(ΔFc) Antibodies From ANDV Vaccinated Geese are Capable of Virus
Neutralization In Vitro
Based on results from previous experiments showing the ability of IgY/IgY(ΔFc)
antibodies from goose eggs to recognize epitopes on the ANDV glycoproteins, we next
looked at the neutralizing capabilities of the antibodies. Initially the ANDV-neutralizing
abilities of anti-ANDV IgY/IgY(ΔFc) antibodies were determined for serum samples
taken from vaccinated geese on weeks 0, 4, 6, 8, 10, and 12 using the in vitro PsVNA
assay. PsVNA80 results show that after the initial vaccination anti-ANDV IgY/IgY(ΔFc)
antibodies were highly neutralizing with PsVNA80 titers ranging between 1,000 and
10,000 just four weeks into the experiment (Fig. 7). Neutralizing titer levels remained
stable during all of the experimental time points, and titers were still detectable at week
12 (Fig 7, right side week 0). The neutralizing titers were also maintained during the year
in between immunizations. PsVNA80 titers of serum samples taken just prior to longrange booster vaccination were similar to those of the vaccinated naïve birds.
Surprisingly, when geese were given a booster vaccination, neutralizing antibody titers of
the sera were increased to nearly 100,000 (Fig. 7).
It has already been well established that in geese IgY is transferred from the sera
to the egg yolk; because of this we predicted IgY/IgY(ΔFc) antibodies from the egg yolks
of vaccinated geese would have similar ANDV neutralizing abilities as sera from
vaccinated geese. To test this PsVNA80 neutralizing titers were determined for
IgY/IgY(ΔFc) antibodies isolated from eggs collected after the initial vaccination series
and the long-range booster vaccination. PsVNA80 titers for IgY/IgY(ΔFc) antibodies
isolated from eggs collected after the initial series of vaccinations were within the same
range as the sera from DNA vaccinated geese collected 1,000-10,000 (Fig 8). After long92

range booster vaccination series eggs were collected and IgY/IgY(ΔFc) from these egg
yolks reached PsVNA80 titers of 100,000 for both geese boosted with pWRG/ANDM(opt) and pWRG/AND-M(opt2) (Fig 8). IgY/IgY(ΔFc) egg yolk PsVNA80 titers also
correlate with the epitope mapping data that shows increased reactivity to nearly all of the
epitopes recognized after the initial immunization, and additional regions of
IgY/IgY(ΔFc) antibody binding after booster vaccination. This data suggests that better
neutralizing antibodies are made after the booster vaccination series.
ANDV Specific Goose IgY/IgY(ΔFc) Antibodies Treat ANDV Challenged Syrian
Hamsters In Vivo
Based on the neutralizing capabilities of the goose anti-ANDV IgY/IgY(ΔFc)
antibodies in vitro and previous success with passive treatment using duck IgY [427], we
were interested in testing the goose anti-ANDV IgY/IgY(ΔFc) in vivo. To test the in vivo
therapeutic treatment potential of ANDV specific goose IgY/IgY(ΔFc) antibodies, groups
of eight Syrian hamsters were lethally challenged i.m. with 250 LD50 doses of ANDV.
Five and eight days later the hamsters were passively treated with one of the six
following treatments: (1) anti-ANDV rabbit sera from DNA vaccinated rabbits (positive
control), (2) anti-ANDV goose sera (from DNA vaccinated geese), (3) anti-ANDV
purified IgY/IgY/(ΔFc) antibodies (from the eggs of DNA vaccinated geese), (4) normal
goose sera, (5) normal purified IgY/IgY(ΔFc) antibodies, (6) no treatment (Fig 9A).
Hamsters that receive normal goose sera, normal purified goose IgY, or no treatment
started to die at day 12 with most of them dying by day 14. In contrast, there was 100%
survival in the groups of hamsters receiving either the anti-ANDV goose sera or antiANDV purified IgY/IgY(ΔFc) antibodies. The 100% survival in the ANDV- specific
IgY treatment groups was just slightly better than the 90% survival for the anti-ANDV
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rabbit sera, the difference was not statistically significant (Fig 9B). These results
demonstrate that anti- ANDV goose IgY/IgY(ΔFc) antibodies are capable of being used
as a treatment for ANDV lethal challenge in vivo when administered five and eight days
post-challenge in Syrian hamsters.

94

Figure 7. Neutralizing activity of anti-ANDV IgY/IgY(ΔFc) antibodies from serum of
ANDV DNA vaccinated geese analyzed in vitro. Neutralizing abilities of anti-ANDV
IgY/IgY(ΔFc) antibodies in goose sera was measured by PsVNA. On the left, PsVNA
were run on sera collected during the initial vaccination series on weeks 0, 4, 6, 8, 10, and
12. On the right, PsVNA were run on sera collected before and after the booster
vaccination series on weeks 52, 55, 56, 60, and 63. ID and results for individual animals
are shown where Group A has black lines and Group B has red lines. Group A was
boosted with pWRG/AND-M(opt) and Group B was boosted with pWRG/AND-M(opt2).
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Figure 8. In vitro neutralizing activity of anti-ANDV IgY/IgY(ΔFc) antibodies isolated
from the eggs of ANDV DNA vaccinated geese. Neutralizing activity of IgY/IgY(Fc)
isolated from the individual eggs of geese after initial and booster DNA vaccination was
measured by PsVNA. PsVNA values for IgY/IgY(ΔFc) isolated from eggs collected
from geese after initial vaccination are to the left of the center and to the right are PsVNA
values for IgY/IgY(ΔFc) from eggs collected after booster vaccination. Each sample was
run in triplicate and bars represent standard deviation.
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A

Group 1: anti-ANDV rabbit sera (+ control)
Group 2: anti-ANDV goose sera
Group 3: anti-ANDV purified IgY
Group 4: normal goose sera
Group 5: normal purified IgY
Group 6: no treatment

B

Figure 9. Anti-ANDV IgY/IgY(ΔFc) antibodies purified from goose eggs treats hamsters
against lethal ANDV challenge when administered after challenge. A) Experimental
design. Six groups of eight hamsters were challenge with 250 LD50 of ANDV by i.m.
route on day 0. Groups of eight hamsters were then passively treated with the indicated
material on days five and eight post-challenge. Sera from a previously ANDV vaccinated
rabbit served as a positive control. B) Survival curve of hamsters that were challenged
and then passively treated.
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Discussion
ANDV has been associated with most HPS cases [363] and continues to be the
only hantavirus capable of human-to-human transmission. In spite of the continuing
number of HPS cases and the staggering mortality rate of approximately 40%, there are
no available treatments or preventative vaccines. The potential for the use of passive
treatments to protect against HPS has already been established by previous studies
utilizing immune serum from infected patients and isolated antibodies from vaccinated
animals in the ANDV/hamster model [425-427]. In addition, research using HPS patients
has highlighted the importance of neutralizing antibody production in recovery from
infection [423,424]. A clear source of antibodies for passive treatment would be immune
plasma from recovered patients, but immune plasma is in short supply, can pose
problems of reactogenicity when given to other patients, and can be contaminated with
other infectious pathogns. Protective monoclonal antibodies are another option for
treatment and have been used with other viral infections [429], but thus far there have
been no identified ANDV-neutralizing monoclonal antibodies.
As an alternative source, polyclonal antibodies have been generated against toxins
and venoms in vaccinated sheep and horses, but this method has yet to be successful in
generating any anti-viral treatments. Avian antibodies are again a logical alternative
source of passive therapeutics with the potential to overcome the shortcomings of current
therapeutic antibodies be it limitations in source, reactivity to Fc portions of mammalian
antibodies, or lack of reactivity with neutralizing epitopes. IgY is the primary serum
antibody of birds and is transferred to the egg yolk via receptors on the surface of the
yolk membrane, that is specific for IgY antibody translocation, causing the yolk to have
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high IgY antibody concentrations [21,25-27,44]. IgY can then be purified from egg yolks
and in large quantities for use as therapeutics. Current and previous research using
polyclonal avian IgY antibodies has already established a baseline for its therapeutic
potential against infectious agents e.g. Pseudomonas aeruginosa [66,108,120,430] and
Candida albicans [431]. IgY antibodies have also been developed against different
venoms and antitoxins [202,205,206,432-434]. Most important for our research, DNA
vaccinated birds have also been used to produce virus- specific IgY antibodies
[427,435,436].
There was a direct relationship between the ANDV neutralizing titers of
IgY/IgY(ΔFc) antibodies from both the serum and eggs of vaccinated geese after the
initial and booster vaccination series. PsVNA80 titers for sera from DNA vaccinated
geese increased from a range of 1,000-10,000 just four weeks into the initial vaccination
series, to nearly 100,000 three weeks into booster vaccination (Fig 7). In this current
study, it has also been shown that neutralizing titers were maintained during the year in
between initial vaccination and booster vaccination. Neutralizing titers measured 12
weeks into the initial vaccination series and just prior to booster vaccination stayed in the
1,000-10,000 range for PsVNA80 values (Fig 7). These results are important because
during a typical response most animals and humans show a decrease in antibody titers a
few weeks after vaccination and a drop would certainly be expected a year after
vaccination. More importantly, when geese were booster vaccinated, IgY/IgY(ΔFc)
antibodies from the sera of some geese reached PsVNA80 neutralizing titers of 100,000
(Fig 7). Similar trends were observed for PsVNA80 titers of goose anti-ANDV
IgY/IgY(ΔFc) antibodies isolated from the eggs of vaccinated geese. After initial
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vaccination PsVNA80, titers for individual eggs ranged between 1,000 and 10,000.
Booster vaccination resulted in an increase in egg IgY/IgY (ΔFc) antibody titers to nearly
100,000 (Fig 8). In similarly designed experiments Brocato et al. reported that DNA
vaccination of ducks with pWRG/AND-M resulted in the production of ANDV
neutralizing antibodies[427]. But, ANDV specific duck IgY/IgY(ΔFc) antibodies
purified from egg yolks of vaccinated ducks only reached neutralizing PRNT80 titers of
10,240. These neutralizing titer values were lower than the neutralizing ANDV goose
IgY antibody titers obtained in this study. Current results point out the advantage of
administering a long-range booster vaccination in the use of pWRG/AND-M and that
IgY/IgY(ΔFc) antibodies purified from egg yolks after booster vaccination represent a
better option for post-exposure IgY antibody treatments due to the increased neutralizing
capabilities of the antibodies.
Epitope mapping completed using IgY/IgY(ΔFc), IgY, and IgY(ΔFc) antibodies
purified from egg yolks of vaccinated geese identified several regions of reactivity on the
ANDV surface glycoproteins G1 and G2. Some of these regions are likely to represent
neutralizing ANDV epitopes. In other hantavirus infections, neutralizing activity has
been related to antibodies directed to the surface proteins. Monoclonal antibodies to G1
and G2, but not to N, have been shown to neutralize viral infection in vitro [437]. This
matches what is seen in natural hantavirus infections in humans, where antibodies are
made predominantly against the N protein, followed by the glycoproteins [438,439].
From the initial vaccination there were 11 epitopes recognized by IgY/IgY(ΔFc)
antibodies and after the long-range booster vaccination there were an additional nine
epitopes recognized by IgY/IgY(ΔFc) antibodies. There were two regions with the
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highest reactivity; for all IgY antibody treatments, spanning peptides starting with aa
613-625 in G1 and aa 727-742 in G2. Looking at the predicted structure of the ANDV
glycoproteins as part of a mature virion, aa 613-625 are part of the endomembrane
domain prior to the WAASA cleavage site. This cleavage site is found at aa 647-651,
where the glycoprotein precursor is cleaved into the two glycoproteins G1 and G2 [428].
The secondary structure of this region is predicted to be primarily α-helices. For the G2
glycoprotein’s highly reactive region, aa 727-742, is within the outer membrane domain
of the protein and the secondary structure primarily made of β-sheets and random coils.
The highly reactive regions in glycoproteins G1 and G2 do not overlap with regions
previously identified as reactive by serum from human ANDV HPS patients, or serum
from naturally infected rodents [428]. In addition, the highly reactive IgY antibody
epitopes do not overlap with regions recognized by monoclonal antibodies (mAb) which
neutralize other hantaviruses [440-442]. The only overlap with human and rodent
epitopes was seen with IgY/IgY(ΔFc) anitbodies from egg yolks after long-range booster
vaccination, specifically aa 691-710. After initial vaccination, this region was hardly
recognized by IgY/IgY(ΔFc) antibodies, but after long–range booster vaccination
IgY/IgY(ΔFc) antibody reactivity increased, especially the peptide starting with aa 694,
which reached the highest reactivity potential (Fig 6). This is a potentially
immunodominant domain since it is being recognized by antibodies from multiple
species. The other two highly reactive regions recognized by the IgY/IgY(ΔFc)
anitbodies from the egg yolks of booster vaccinated geese, represent novel, potentially
neutralizing epitopes on the ANDV glycoproteins that can be used in the future to
develop mAb therapies.
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Future work will focus on using results from the epitope mapping experiments to
develop cocktails of ANDV neutralizing mAbs. A treatment that has the potential to be
more effective could be developed by specifically targeting epitopes that are neutralizing.
This can lower the total antibody dose that needs to be administered and in turn lowers
the chance of any adverse reactions to the treatment. This, coupled with the decreased
reactogenicity due to the natural properties of goose IgY antibodies, leads to the
opportunity to develop an all-around better treatment option for ANDV and other viral
agents. This potential has been previously explored in our lab with Dengue virus and
West Nile Virus (data not shown).
Previous research has already established the success of passive treatments for
ANDV infection utilizing sera from animals vaccinated against ANDV. When passively
transferred to Syrian hamsters one day prior to lethal challenged with ANDV (250 LD50
i.m.), serum from rehesus macaques vaccinated against ANDV was able to protect
against infection [425]. The same serum was also able to reverse ANDV infections when
administered either four or five days after challenge [425]. During this study the postexposure treatment potential of plasma from a Chilean ANDV HPS patient that was
collected during the convalescent-phase was also compared. When the convalescent
plasma was administered at four or five days post-challenge only 50% of hamsters
survived. Through previous survival studies in ANDV challenged hamsters using
IgY/IgY(ΔFc) antibodies from the eggs of ducks vaccinated with pWRG/AND-M, it was
concluded that high doses of ANDV- specific IgY/IgY(ΔFc) antibodies administered
within eight days of exposure to virus is sufficient to contain and suppress the infection
[427]. Notably, in this research, anti-ANDV goose IgY/IgY(ΔFc) antibodies were
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administered at five and eight days post-challenge with ANDV in hamsters and there was
100% survival, while treatment with non-specific IgY antibodies, or no treatment led to
death of nearly all the hamsters in those treatment groups (Fig 9).
These results demonstrate the in vivo efficacy of ANDV specific goose
IgY/IgY(ΔFc) antibodies and the successful coupling of DNA vaccination with the
extraction of therapeutic antibodies from the eggs of vaccinated geese. ANDV specific
goose IgY/IgY(ΔFc) antibody treatments had a slightly better survival percentage than
the anti-ANDV rabbit sera treated group. Therefore it is possible that antibodies from
vaccinated animals have better virus neutralizing capabilities than those found in human
convalescent serum, or that the antibody response is being directed towards highly
neutralizing epitopes as a result of vaccination. To further support this, Brocato et al.
also showed that IgY/IgY(ΔFc) antibodies isolated from the eggs of vaccinated ducks had
higher plaque reduction values at lower concentrations than fresh frozen plasma (FFP)
from a survivor of ANDV HPS[427].
This research demonstrates the potential to use goose IgY/IgY(ΔFc) antibodies as
a post-exposure treatment for HPS caused by ANDV. Results both in vitro and in vivo
clearly show the viral specificity and neutralizing capabilities of the anti-ADNV goose
IgY antibodies. The decreased reactivity of IgY antibodies in the mammalian system
makes it an ideal alternative to the rare and potentially dangerous human FFP.
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CHAPTER IV
SAFETY OF GOOSE IGY FOR USE IN THE MAMMLIAN SYSTEM
Introduction
It has been demonstrated that avian IgY/IgY(ΔFc) antibodies do not interact with
the human complement system, rheumatoid factor (RF), or bacterial pathogens that are
Fc-binding, and generate less of a human anti-murine antibodies (HAMA)/anti-drug
antibody (ADA) response than mammalian IgG antibodies. This lack of reactivity in the
mammalian system is mostly due to the structure of the Fc portion of avian IgY/IgY(ΔFc)
antibodies and how it differs from mammalian IgG.
HAMAs form often when antibodies are used for treatment or imaging; the
murine antibody is seen as a foreign protein by the human body, which triggers an
immune response resulting in the formation of HAMAs. In some cases HAMAs have
also been found in the serum of patients who have not been treated with antibodies [66].
The HAMA response can persist in the blood for several months, and can be easily
reactivated if memory B-cells are formed. This response can interfere with assays used
in diagnosis and/or surveillance of disease as well as cause potentially painful symptoms
for the patients. Even engineered antibodies have protein epitopes that can be seen as
immunogenic by the immune system and ultimately cause an antibody response by the
body. The HAMA/ADA responses within the body can result in a variety of symptoms
from more mild allergic reactions, generalized pain, hyponatremia, fever, rigors, chills,
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rash, paresthesia, weakness, chronic refractory postural hypotension [67,68], to
hypersensitivity reactions that range from serum sickness with urticarial and
bronchosapsms [68-72] to anaphylactic shock [73-75].
The structural differences between mammalian IgG antibodies and avian IgY
antibodies are especially important in their interactions with complement proteins and
RF. The heavy chain of the full length IgY antibody is made up of one variable domain
and four constant domains, three of which make up the Fc region. The alternatively
spliced (IgY(ΔFc)) antibody isotype has one variable domain and one constant domain
[44]. In contrast, the heavy chain of mammalian IgG antibody has one variable domain
and only three constant domains, two of which make up the Fc region [44]. The
interaction of mammalian IgG antibody with complement proteins and RF can result in
unwated inflammatory reponses in the body. When the complement pathway is
inappropriately activated it can lead unnecessary inflammatory reactions. The
anaphylatoxins, C4a, and C5a, products of the complement pathway, are often
responsible for initiating parts of these inflammatory responses. Anaphylatoxins are able
to stimulate mast cells to trigger IgE-independent histamine release as well as TNF-α
release [89], wich can mimic allergic shock depending on the number of mast cells
involved [90,91]. In humans, a Serum sickness-like illness can also develop depending
on the number of complement immune complexes formed during the course of treatment.
Most studies on the differences in the reactivity of avian, compared to
mammalian, immunoglobulin have been performed in vitro. In ELISAs comparing goat
and chicken antibodies as capture antibodies to normal human serum (NHS), it has been
shown that complement activation blocked up to 50% of antigen binding when using goat
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antibodies, but an active complement system had no effect on antigen binding when
chicken antibodies were used as a capture antibody [94]. In sandwich ELISAs used for
the detection of antigens in human samples, the anti-mammalian IgG antibody RF can
interfere and cause false positive results. These false positives can be avoided by the use
of avian IgY antibodies [84].
The aim of this research is to determine the reactivity of goose IgY/IgY(ΔFc) and
IgY(ΔFc) antibodies within the mammalian system utilizing in vitro peripheral blood
monocyte assays, neutrophil assays, and in vivo injection studies to look at organ
pathology for any damage due to inflammation. Previous research has proven the
effectiveness of goose IgY/IgY(ΔFc) antibodies as potential treatments. The next step to
using goose IgY/IgY(ΔFc) antibodies as human passive antibody treatments is to
establish their safety. We show here for the first time in vitro and in vivo experiments
testing the reactivity of IgY within the mammalian system.

Materials and Methods
Mice
Mice were injected intravenously (i.v.) with either 200μg of goose IgY in 200μL
of 1X PBS pH 7.4 (Invitrogen, Carlsbad, CA, USA) or 200uL of 1X PBS alone on
experimental day 0. Tissues were collected from IgY injected mice on experimental days
0, 6hr, 2, 4, 7, 14, and 28. Tissues were collected from control injected mice, PBS alone,
on experimental days 0 and 14. On day 28 mice were euthanized and the following
tissues were collected: brain, heart, lung, liver, spleen, and kidney. Blood was collected
from mice prior to euthanization.
Histology
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Mouse tissues were fixed in a 10% neutral buffered formalin solution (Fisher
Scientific, Hampton, NH, USA). Fixed tissues were sent to AML laboratories
(Baltimore, MD, USA) for paraffin embedding, sectioning, and hematoxylin and eosin
staining. Stained tissues sections were then viewed and scored by a blinded pathologist.
Rabbits
Thirty adult female rabbits were divided into three experimental groups and one
control group. Rabbits in experimental group one were injected with 10mg of
commercially available human anti-rabies antibody HRIG, HyperRAB® (Grifols, Los
Angeles, CA, USA ). Rabbits in experimental group two were injected with 10mg of
total goose anti-rabies IgY antibodies (IgY/IgY(ΔFc)). Rabbits in experimental group
three were injected with goose anti-rabies IgY(ΔFc). Rabbits in the control group were
inject with 1X PBS, p.H. 7.2. Treatments were administered via i.m. injections on
experimental days 0, 7, 14, 28, and 42. Sera was collected from treated rabbits on
experimental days 0, 14, 28, and 42. Four weeks after the last injection, experimental day
70, rabbits were terminally bled and euthanized. The spleen, thymus, lymph nodes,
kidneys, hearts, liver, and brain were collected, fixed, H&E stained, and scored by a
blinded pathologist.
Human PBMC Cell Culture
Peripheral blood monocytes (PBMCs) were isolated from whole blood of healthy
human donors and resuspended at a concentration of 2.0x106 cells/mL in RPMI 1640
culture media supplemented with 2mM L-glutamine, 10mM HEPES, 100ug/mL
streptomycin, and 100U/mL penicillin. Then, 500μL of the cell suspension was added to
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wells of a 24-well tissue culture plate. Next, 500μL of cell treatment at twice the final
concentration in culture media or an additional 500μL of cells (negative control) was
added to the wells. Cells were treated with lipopolysaccharide (LPS) (10μg/mL),
mammalian IgG antibody (10μg/mL), and goose IgY/IgY(ΔFc) antibody (10μg/mL).
Plates were incubated for 72 hours at 37ºC with 5% CO2. Culture supernatants were
collected at 12, 24, 48, and 72 hours and frozen for later cytokine analysis.
Human Neutrophil Cell Culture
Neutrophils were isolated from healthy human blood using Histopaque (Sigma
Aldrich, MO, USA). Isolated neutrophils were resuspened in RPMI 1640 containing 1%
BSA at a concentration of 5x105 cells per mL. Then, 100uL of cell suspension was added
to wells of a 96-well tissue culture plate. Cells were treated with PMA diluted 1:1000
(positive control), culture media alone (negative control), LPS (10μg/mL), mammalian
IgG antibody (10μg/mL), and goose IgY/IgY(ΔFc) antibody (10μg/mL). Plates were
incubated for 72 hours at 37ºC with 5% CO2. Culture supernatants were collected at 12,
24, 48, and 72 hours and frozen for later analysis. Elastase levels in culture supernatants
were quantified using a fluorometric assay kit (Cayman Chemical, Ann Arbor, MI, USA).
Cytokine Analysis
Cytokine levels in culture supernatants were quantified by ELISA using
commercially available kits. The IL-1β kit was obtained from R&D systems,
Minneapolis, MN. TNF-α and IL- 10 levels were quantified using BD Opt-EIA™
ELISA kits (BD Biosciences, San Diego, CA, USA). Nitric oxide (NO) levels in the
culture supernatant were measured through a Griess assay utilizing a commercially
available kit from Promega, Madison, WI. The colorimetric change of each well was
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determined at various optical densities using a Thermomax Microplate Reader
(Molecular Devices, Sunnyvale, CA, USA).
Statistical Analysis
Statistical analysis was carried out using the two-way ANOVA and Bonferroni’s
multiple comparison tests. P value <0.05 was considered statistically significant unless
otherwise noted. Data was plotted as calculated sample means with standard deviation.

Results
Injection of IgY/IgY(ΔFc) Antibodies Does Not Induce Abnormal Organ Pathology
in Vivo
The effects of single and multiple injections of avian IgY/IgY(ΔFc) antibodies on
organ pathology was examined in vivo. In the single injection study, mice were injected
with either goose IgY/IgY(ΔFc) antibodies (n=35) or 1X PBS (n=10) via tail vein
injection on experimental day 0. Organs collected from the experimental mice, included
the brain, heart, lung, liver, spleen, and kidney; tissue was fixed, stained with H&E, and
reviewed by a blinded pathologist. Of the six organs that were collected, there were no
abnormal changes found in the brain, heart, liver, kidney, or spleen. The only tissue that
showed any abnormalities was the lungs. Pulmonary hemorrhages were present in a large
number of mice, across both treatment groups. The frequency and severity of
hemorrhages in the lungs was increased on days 14 and 28 (Table 1).
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Table 1. Pathology results from single injection study in mice.
PBS

Brain

Heart

Kidney

Lung

0 hours

-/-1

-/-

-/-

-/-

-/-

2FH/2FH2

14 days

-/-

-/-

-/-

-/-

ARP/ARP3

2FH/2FH

Brain

Heart

Kidney

Lung

0 hours

-/-

-/-

-/-

-/-

-/-

-/-

6 hours

-/-

-/-

-/SC4

-/-

-/-

FH/FH

2 days

-/-

-/-

-/-

-/-

-/-

3FH/3FH

4 days

-/-

-/-

-/-

-/-

-/-

2FH/2FH

7 days

-/-

-/-

-/-

-/-

-/-

3FH/3FH

14 days

-/-

-/-

-/-

-/-

-/-

3FH/3FH,
1MH/1MH5

28 days

-/-

-/-

-/-

-/-

-/-

4FH/4FH,
1MH/1MH

IgY/IgY(ΔFc)

Liver Spleen

Liver Spleen

Results are shown for two pathology slides from a sample size of five mice for each
experimental time point.
1
no change
2
focal hemorrhage (FH) in two of five mice
3
acute inflammation of renal pelvis (ARP) in one of five mice
4
small cyst (SC)
5
moderate hemorrhage (MH) in one of five mice
Rabbits were injected in a multiple injection study, receiving five injections over
a six-week period with either goose anti-rabies IgY/IgY(ΔFc), goose anti-rabies
IgY(ΔFc), human anti-rabies antibodies (HRIG), or control 1X PBS. Four weeks after
the last injection (day 70), all rabbits were euthanized and organs were collected
including the spleen, thymus, lymph nodes, kidneys, heart, lungs, liver, and brain. Rabbit
tissues were scored by a blinded pathologist for inflammation. Inflammation was almost
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exclusively limited to the lungs of experimental rabbits, but there was no difference
observed between treatment groups. Overall, the pathology results indicated that rabbits
receiving multiple injections with either IgY/IgY(ΔFc) or IgY(ΔFc) antibodies showed
no signs of abnormal pathology when compared to the rabbits that received multiple
injections of HRIG or 1X PBS (Table 2). The results of the single and multiple injection
studies further support the non-inflammatory nature of avian IgY in the mammalian
system.
Table 2. Pathology results for organs collected from rabbits in the multiple injection
study.
Rabbit

Brain1

Thymus2

Lung3

Heart4

Liver5

Kidney6

Spleen7

Treatment

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

2
3
1
0
0
2
0
2
0
2
2
1
0
1
1
2
0
0
2
1
0
3
1
1
2
2
2

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
2
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
2
0
0
0
2
0
0
1
1
1
0
2
1
0
0
0
0
0
0
2
1
0
0
0

HRIG
HRIG
HRIG
HRIG
HRIG
HRIG
HRIG
HRIG
IgY/IgY(ΔFc)
IgY/IgY(ΔFc)
IgY/IgY(ΔFc)
IgY/IgY(ΔFc)
IgY/IgY(ΔFc)
IgY/IgY(ΔFc)
IgY/IgY(ΔFc)
IgY/IgY(ΔFc)
IgY(ΔFc)
IgY(ΔFc)
IgY(ΔFc)
IgY(ΔFc)c
IgY(ΔFc)
IgY(ΔFc)
IgY(ΔFc)
IgY(ΔFc)
PBS
PBS
PBS
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Table 2. Cont.
28
0
0
0
0
0
0
0
PBS
29
0
0
1
0
0
0
1
PBS
30
0
0
2
0
0
0
0
PBS
1,4,6
Brain, Kidney, and Heart: 0= no change; 1= minimal change; 2= mild change; 3=
moderate change; 4= marked changes but restricted extent; 5= marked and widespread
changes; 6= very severe, diffuse changes
3
Lung: 0= no change; 1= minimal change (or possible non-specific background or
appearance compounded by lung collapse i.e. not inflated); 2= mild inflammation and/or
pneumocyte hypertrophy; 3= moderate inflammation inflation and/or pneumocyte
hypertrophy; 4= marked inflammation and/or pneumocyte hypertrophy; 5= severe
inflammation and/or pneumocyte hypertrophy < 50% of lung lobe
7
Spleen: 0= no change; 1= mildly increased extramedullary hematopoiesis (EMH); 2=
moderately increased EMH and/or mild inflammation; 3= marked EMF and/or moderate
inflammation; 4= marked inflammation; 5= severe inflammation; 6= severe necrotizing
inflammation.
IgY/IgY(ΔFc) Antibodies Do Not Induce Notable Proinflammatory Mediator
Release From Human PBMCs or Neutrophils
To better understand the reactivity of avian IgY/IgY(ΔFc) in the mammalian
system and the capacity of avian IgY/IgY(ΔFc) antibodies to activate human immune
cells and initiate an inflammatory reaction, human PBMCs and neutrophils were isolated
from healthy human blood and then incubated in vitro with mammalian IgG antibodies or
avian IgY/IgY(ΔFc) antibodies, and cells incubated with LPS served as a positive control
and cells alone as a negative control. Culture supernatants were collected 0, 12, 24, 48,
or 72 hours from start of incubation depending on the analysis being completed. Culture
supernatants collected from treated PBMCs were analyzed for the release of cytokines,
including proinflammatory cytokines IL-1β and TNF-α, anti-inflammatory cytokine IL10, and nitric oxide (NO).
IL-1β was not detected as a result of IgY/IgY(ΔFc) antibody treatment at 12, 24,
and 48 hours post-treatment, with a modest level of IL-1β observed at 72 hours (Fig 10).
This is compared to a consistent amount of IL-1β being produced by mammalin IgG
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treated PBMCs as indicated by the 5pg/mL concentration present in culture supernatants
from 12 hours post-treatment to the final time point, and gnificant amounts of IL-1β
generated by LPS treatment of PBMCs. TNF-α was not detected via ELISA in the
culture supernatants collected from PBMCs incubated with IgY/IgY(ΔFc) antibodies (Fig
11). In contrast, TNF-α levels from cells incubated with LPS were at high throughout
with the highest levels being measured at 72 hours post-treatment. The difference
between the LPS treated PBMCs and all other groups was statistically significant. Only
at one point, 24 hours post-treatment, did IgG treated PBMCs produce any TNF-α (Fig
11). The difference between IgY/IgY(ΔFc) antibody and IgG antibody treated cells was
not significant. The IL-1β and TNF-α results correlate with the pathology results from
the single and multiple injection studies, supporting the finding that IgY/IgY(ΔFc)
antibody does not cause abnormal inflammatory responses. Levels of the antiinflammatory cytokine IL-10 were also quantified in culture supernatants from treated
PBMCs. No IL-10 was detected by ELISA with all treatments at all time points (data not
shown).
Nitrite levels in culture supernatants collected from PBMCs were quantified as an
indicator of NO production by the cells. Cells treated with IgY/IgY(ΔFc) antibodies
showed a peak in nitrite levels at 24 hours with levels decreasing afterward (Fig 12). IgG
antibody treated cells showed a stable increase in nitrite levels from 0 hours all the way
up to 72 hours of incubation. There was no noticeable difference in the nitrite levels in
culture supernatants collected from cells incubated with IgY/IgY(ΔFc) antibodies
compared to those incubated with IgG antibodies. The nitrite levels generated by
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IgY/IgY(ΔFc) antibody treatment of PBMCs were well below a level of concern during
an inflammatory response.
The potential reactivity of IgY/IgY(ΔFc) with human neutrophils was also
assessed. Neutrophils were isolated from the blood of healthy human donors and then
co-cultured in vitro with mammalian IgG antibodies, avian IgY/IgY(ΔFc) antibodies,
PMA (which is known to activate neutrophils leading to elastase release), and LPS.
Untreated cells, served as a negative control. Activation of neutrophils by the various
treatments was determined by the amount of elastase present in neutrophil culture
supernatants at 12, 24, and 72 hours after treatment. Treatment of cells with
IgY/IgY(ΔFc) antibodies resulted in the release of elastase by neutrophils, but levels were
lower than all other treatments at 12 hours and slightly lower than all other groups at 72
hours as well (Fig 13). There was no difference in the release of elastase between
neutrophils treated with mammalian IgG and those treated with IgY/IgY(ΔFc).
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⃰

⃰

⃰

Figure 10. IL-1β concentration in culture supernatants from treated human PBMCs. IL1β levels were analyzed in culture supernatants collected from PBMCs stimulated with
mammalian IgG antibodies, goose IgY/IgY(ΔFc) antibodies, LPS (positive control), or
cells only (negative control). IL-1β levels were quantified using an ELISA. Culture
supernatants were collected at hours 0, 12, 24, 48, and 72 hours post-treatment of cells.
Each data set is a mean of three samples with the bars representing the standard
deviation. Two-way ANOVA and Bonferroni’s Multiple Comparison tests were
completed for statistical analysis. ( ⃰ ) indicatates significant distances between
IgY/IgY(ΔFc) treatment of cells and LPS treatment of cells (P< 0.001).
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⃰
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⃰

Figure 11. TNF-α levels in culture supernatants from treated human PBMCs. PBMCs
were treated with either goose IgY/IgY(ΔFc) antibodies, mammalian IgG antibodies,
LPS, or left untreated. Culture supernatants were collected 0, 12, 24, 48, and 72 hours
after incubation. TNF-α levels in the culture supernatants were quantified using an
ELISA. ( ⃰ ) indicates a significant difference between IgY/IgY(ΔFc) treated PBMCs and
LPS treated PBMCs (P< .0001). Statiscal analysis completed was a Two-way ANOVA
and Bonferroni’s Multiple Comparison tests.
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Figure 12. Nitrite concentration in culture supernatants from treated human PBMCs. A
Griess assay measuring nitrite concentrations in culture supernatants was used as an
indicator of the amount of nitric oxide released by treated PBMCs. Culture supernatants
were collected from PBMCs treated with goose IgY/IgY(ΔFc) antibodies, mammalian
IgG antibodies, LPS, or untreated cells. Nitrite levels in the culture supernatants
collected at 0, 12, 24, 48, and 72 hours post-treatment were quantified using a Griess
assay; absorbance was read at an OD between 520 to 540nm. The mean for each data
point is shown, with the bars representing the standard deviation.
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Figure 13. Neutrophil elastase levels in cultured supernatants from treated human
neutrophils. Culture supernatants were collected from human neutrophils treated with
IgY/IgY(ΔFc) antibodies, mammalian IgG antibodies, PMA (positive control), LPS
(positive contro), or untreated cells (negative control) 12, 24, and 72 hours after
treatment. Neutrophil elastase levels were quantified using a kit containing a nonflourescent elastase substrate, which is selectively cleaved by elastase to generate a
highly fluorescent compound R110 that can be read at an excitation wavelength of
485nm and an emission wavelength of 525nm. Each data point represents a mean ±
standard deviation.
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Discussion
In this study we present data to support the structural evidence that the use of
avian IgY and IgY(ΔFc) antibodies in the mammalian system does not result in abnormal
inflammatory responses. The Fc portion of the mammalian antibody serves an important
role in triggering many biological responses such as phagocytosis, endocytosis, antibodydependent cellular cytotoxicity, and release of inflammatory mediators, but inappropriate
interaction of the Fc portion of antibodies with FcR can result in unnecessary
inflammatory reactions. These types of inflammatory reactions are sometimes seen when
mammalian antibodies are used as passive antibody treatments. HAMA and ADA
responses can also form, resulting in an array of painful symptoms. Structurally the Fc
portion of avian IgY antibody is different than that of mammalian IgG antibody and is
unable to interact with mammalian FcγR and activate immune pathways that can lead to
unwanted inflammation [88,94]. Current and previous research has demonstrated that
avian IgY/IgY(ΔFc) antibodies isolated from the eggs of vaccinated birds can be used
effectively as a passive treatment against various antigens including bacteria and viruses.
In our lab specifically, we have investigated and proven the effectiveness of goose
IgY/IgY(ΔFc) antibodies in vivo as post-exposure treatment for hantavirus pulmonary
syndrome caused by the Andes virus. The purpose of this study was to determine the
reactivity of avian IgY/IgY(ΔFc) antibodies and IgY(ΔFc) antibodies in the mammalian
system to ensure its safety moving forward towards an increased use in humans.
In both the single and multiple injection studies animals receiving IgY/IgY(ΔFc)
antibodies or IgY(ΔFc) antibodies did not show any abnormal pathology or inflammation
compared to control animals injected with PBS or HRIG. The only organ to show any
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consistent abnormal pathology in both studies was the lungs. Abnormalities observed in
the lungs were not dependent on treatment. Mice or rabbits in all treatment groups (IgY,
PBS, or HRIG) developed hemorrhages or inflammation in the lung depending on how it
was characterized in the study. In the single injection study, hemorrhaging did get worse
at later time points, but again the severity and frequency of occurrence was the same
between the control and experimental groups. The abnormal pathology in the lungs is
therefore not dependent on treatment with IgY, PBS or HRIG specifically.
In this study we were able to show that IgY/IgY(ΔFc) antibody is safe for use in
humans. Goose IgY/IgY(ΔFc) antibodies were incubated in vitro with humans PBMCs
and the production of select pro- and anti-inflammatory mediators was measured. TNF-α
and IL-1β are both proinflammatory cytokines produced by various immune cell types
within the PBMC cell population. Both of these cytokines are produced early in the
immune response. TNF-α is produced primarily by macrophages and promotes
inflammation, activation of endothelial cells and allows extraversion of dendritic cells to
the lymph node, further augmenting the immune response. IL-1β is produced by
dendritic cells and macrophages; it can help to activate other immune cells including Tcells. Our results indicate the PBMCs treated with goose IgY/IgY(ΔFc) antibodies
produce only negligible amounts of IL-1β and no TNF-α compared to the positive control
(Fig 10 and 11). These results provide further evidence that IgY/IgY(ΔFc) antibody is
safe for use within humans. IL-10 is an anti-inflammatory cytokine able to inhibit
activation and effector function of T-cells, monocytes, and macrophages. Ultimately IL10 is responsible for terminating inflammatory responses, but also plays a role in
regulating growth and differentiation of some immune cell populations [443]. When
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cells were treated with IgY/IgY(ΔFc) antibodies there was no IL-10 detected in culture
supernatants collected. There was also no IL-10 produced by any other of the cell
treatments. It is unlikely that IgY/IgY(ΔFc) antibody is immunomodulatory and able to
induce an anti-inflammatory environment.
The activity of NO in inflammation is less well understood than that of the
cytokine previously described. It is known that NO is released by activated macrophages
and is known to regulate the activity, growth, and death of many immune and
inflammatory cells including macrophages and T-lymphocytes [444]. Production of NO
by PBMCs is indicative of immune cell activation and an ongoing inflammatory
response. There was no difference between the NO levels of PBMCs treated with
mammalian IgG and those treated with IgY/IgY(ΔFc) antibodies. Although there were
low levels produced by cells treated with IgY/IgY(ΔFc) antibodies, the effects of NO are
dependent on local concentration and levels produced by treated cells were low enough to
not be of concern.
In order to look at the reactivity of IgY/IgY(ΔFc) antibodies with another
population of innate immune cells, elastase release from activated neutrophils was
measured. Neutrophils are relatively short lived white blood cells that can function in
several ways at the site of inflammation including phagocytosis, cytokine release, and
degranulation [445]. Neutrophil elastase is an active enzyme stored within the granules
of neutrophils until the cells are activated. Upon activation neutrophil elastase can be
excreted from the cell as a free protein or be associated with networks of extracellular
traps (NETs) [446]. Neutrophil elastase is a serine proteinase that can attack a number of
host proteins outside of the neutrophil and can have a damaging effect on host tissues if
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release is triggered unintentionally [447]. Previous research seeking neutrophil elastase
inhibitors alluded to the ability of mammalian IgG being able to actually induce NET
formation [448]. It was therefore important that we test the ability of IgY/IgY(ΔFc)
antibodies to activate neutrophils and lead to elastase release. Treatment of neutrophils
with IgY/IgY(ΔFc) anitbodies led to elastase release, but it took until 24 hours posttreatment to reach levels similar to mammalian IgG (Fig 13). The reason for what
appears to be more activation of human neutrophils over immune cells present in the
human PBMC population is unknown. A better understanding of the direct interaction of
IgY antibodies with mammalian cells is required.
This research demonstrates that IgY/IgY(ΔFc) antibodies are safe for use in the
mammalian system. The single and multiple injection studies along with the in vitro
cytokine data clearly support the structural evidence that IgY/IgY(ΔFc) and IgY(ΔFc)
have limited immunoreactivity within the mammalian system. Based on these results,
IgY continues to remain a viable option for use as passive antibody immunotherapeutics.

122

CHAPTER V
DISCUSSION
In recent years there has been an increased interest in avian-derived antibodies as
a unique source of passive therapeutics. Avian antibodies have the potential to extend
beyond current passive antibody therapeutic technology that primarily utilizes
mammalian antibodies. The majority of mammalian antibodies are of murine origin and
come with the risk of high immunogenicity in humans. IgY is the primary serum
immunoglobulin of birds and is transferred to the egg yolk during embryo development;
this results in the egg yolk having high IgY concentrations [21,44]. The egg yolk then
becomes an easily accessible source of antigen- specific IgY antibodies. Most past and
presently researched avian antibody treatments are polyclonal in origin; in an attempt to
move IgY antibody therapeutics in a new direction part of this current research focused
on the development of a goose monoclonal IgY antibody that could be used to treat
DENV-2 infections. Currently, monoclonal antibody therapeutics are used to treat
transplant rejection [449-451], cancer [452-458], and autoimmune disorders [459-464].
Surprisingly, the use of these treatments for infectious diseases is limited [465]. The
advantages of using avian monoclonal antibodies are three fold: the antibodies produced
by the hybridoma are homogenous, the response generated is consistent, and the need to
collect raw materials from SPF birds is eliminated. In the present study, we were able to
successfully complete the initial stages of hybridoma formation and mAb production, but
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fusions did not last over time. To the best of our knowledge this is the first
demonstration of successful fusion between avian B-cells and mammalian myeloma cells.
Previous research in the area of avian monoclonal antibody development has utilized
chicken myeloma cell lines fused with immune chicken spleen cells [339,341,342].
Despite being unable to develop stable long lasting hybridomas we were able to
successfully show that the vaccinated geese did generate antigen- specific immune
responses, including the production of antibodies, as indicated by the presence of antigenspecific antibodies in goose serum.
Polyclonal avian therapeutics have been developed utilizing chicken IgY
antibodies against various antigenic targets, but the use of IgY antibodies from
anseriformes birds has been limited to only a limited number of viral antigens [427,435].
In our research we focused on ANDV and the development of a polyclonal goose IgY
antibody treatment for HPS caused by ANDV. It is well established that the humoral
immune response is important for a favorable clinical outcome from HPS [350,422-424].
Consistent with findings that virus- specific antibodies play an important role in patient
recovery from HPS, when ANDV- specific goose IgY/IgY(ΔFc) antibodies were given to
hamsters after challenge with a lethal dose of ANDV all of the hamsters survived.
The neutralizing titers of ANDV specific IgY/IgY(ΔFc) antibodies in the serum of
vaccinated geese provided insight into the humoral response of geese. Most interestingly,
neutralizing titers were maintained during the year in between vaccinations. It is
unknown if this type of response is typical of all birds and to all antigens. After booster
vaccination neutralizing titers were nearly ten fold higher. Along with the increase in
neutralizing titers there was also an increase in reactivity of IgY/IgY(ΔFc) antibodies
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isolated from eggs of booster vaccinated geese with epitopes on the surface of both
glycoproteins. The increase in titers and reactivity with epitopes suggests that collecting
antibodies after a booster vaccination series may provide an improved passive IgY
antibody treatment with better neutralizing capabilities.
For the epitope mapping experiments, IgY/IgY(ΔFc) antibodies from the egg
yolks of geese, were separated into the full length (IgY) antibody and alternatively
spliced (IgY(ΔFc)) antibody isotypes, after the initial vaccination series. In general, the
two isotypes reacted with same epitopes on the virus glycoproteins, but there are potential
advantages being able to use only the IgY(ΔFc) isotype. In the avian system IgY(ΔFc) is
unable fix complement or sensitize the tissues to allergic reactions, functions that are
thought to require the Fc portion of the IgY isotype antibody [49]. Even without the
ability to carry out Fc-mediated functions IgY(ΔFc) antibody has still retained its ability
to neutralize viruses within the avian system [44]. Because it is lacking the two constant
domains compared to the full length isotype and one constant domain compared to
mammalian IgG, reactivity within the mammalian system is likely to be limited. Results
from our in vivo multiple injection study indicated there was no abnormal pathology in
rabbits injected with IgY(ΔFc). Future studies looking directly at the reactivity of the
IgY(ΔFc) isotype with human PBMCs may be useful to gain more information on the
inflammatory potential of this specific isotype of IgY.
Regardless of the type of avian antibody treatment being used and the target, the
safety of the treatment for use in the human body is important. In our study we were able
to show through in vivo single and multiple injection studies that treatment of animals
with IgY/IgY(ΔFc) or IgY(ΔFc) antibodies did not result in any abnormal pathology or
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signs of inflammation compared to control animals. Also, IgY/IgY(ΔFc) antibodies did
not induce inflammatory cytokine production by human PBMCs, another indication of
the safety of IgY within the mammalian system. The positive safety results along with
the success of the ANDV- specific IgY/IgY(ΔFc) antibodies as a post-exposure treatment
for HPS caused by ANDV continues to advance the field of avian IgY antibody
treatments towards more human trials.
An important next step in the area of avian antibody treatments is to identify the
receptor on cells in the mammalian system, specifically humans, with which IgY and
IgY(ΔFc) antibodies are able to interact with. Knowing this information would be
helpful in determining what mechanisms IgY and IgY(ΔFc) antibodies use for clearance
of antigens and to generate protection. Also, information about the receptor would be
useful to better understand and test for the potential reactivity of the antibody within
humans, and how potentially the antibody could be modified and still be functional.
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